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ABSTRACT OF DISSERTATION 
 
 
MULTISTATE MARKOV CHAINS AND THEIR APPLICATION TO THE 
BIOLOGICALLY RESILIENT ADULTS IN NUEROLOGICAL STUDIES COHORT 
Dementia is increasingly recognized as a major and growing threat to public 
health worldwide, and there is a critical need for prevention and treatment strategies. 
However, it is necessary that appropriate methodologies are used in the identification of 
risk factors. The purpose of this dissertation research was to develop further the body of 
literature featuring Markov chains as an analytic tool for data derived from longitudinal 
studies of aging and dementia.  
Data drawn from 649 participants in the University of Kentucky’s Alzheimer’s 
Disease Center’s (UK ADC) Biologically Resilient Adults in Neurological Studies 
(BRAiNS) cohort, which was established in 1989 and follows adults age 60 years and 
older who are cognitively normal at baseline to death, were used to  conduct three 
studies. The first study, “Mild cognitive impairment: Statistical models of transition using 
longitudinal clinical data,” shows that mild cognitive impairment is a stable clinical entity 
when a rigorous definition is applied. The second study, “Self-reported head injury and 
risk of cognitive impairment and Alzheimer’s-type pathology in a longitudinal study of 
aging and dementia,” shows that when the competing risk of death is properly accounted 
for, self-reported head injury is a clear risk factor for late-life dementia and is associated 
with increased beta-amyloid deposition in the brain. The third study, “Incorporating 
prior-state dependence among random effects and beta coefficients improves multistate 
Markov chain model fit,” shows that the effect of risk factors, like age, may not be 
constant over time and may be altered based on the subject’s cognitive state and that 
model fit is significantly improved when this is taken into account. 
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CHAPTER ONE 
 
Introduction 
Although commonly used to refer to a disease state, the term “dementia” does not 
refer to a disease at all but rather a syndrome characterized by memory loss and impaired 
activities of daily living (ADLs).1 Multiple neurological diseases can result in dementia, 
the most common of which is late onset, or sporadic, Alzheimer’s disease (AD), which is 
estimated to account for 60 to 80 percent of dementia cases.2  AD is characterized 
clinically by the appearance of deficits in memory, thinking, and ADLs, which are 
common to all dementing illnesses. AD is defined pathologically by the presence of beta-
amyloid (neuritic plaques) and tau (neurofibrillary tangles) pathology, which can only be 
determined by autopsy evaluation; current pathological diagnostic criteria describe levels 
of AD associated changes without regard to clinical phenotype,3 since AD pathology has 
been found in non-demented individuals at autopsy.4,5  
While clinical onset of AD usually occurs after age 65, it is now thought that AD 
begins as long as decades earlier; it is estimated that latent AD exists in approximately 
21% of persons over age 50.6 Prevalence of AD is currently estimated at 5.4 million 
cases, and the Alzheimer’s Association reports that by 2050 that an estimated 16 million 
Americans will have AD.7 Given current costs associated with the care and treatment of 
AD, in 2050 the cost of AD will reach 1.1 trillion dollars.7 At this time, there are no 
effective treatments or prophylactics for AD. 
The term “Mild Cognitive Impairment” (MCI) first appeared in the Global 
Deterioration Scale (GDS),8 a tool for the clinical staging of dementia, to describe 
individuals with subjective memory complaints and objective memory impairments, but 
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without ADL impairment, i.e., without dementia.9 Individuals diagnosed with MCI may 
progress to dementia, remain MCI until death, and in some instances have been reported 
to recover to a normal cognitive state.9-15 For this reason, whether MCI represents an 
early stage of dementia or unique clinical syndrome that is an independent risk factor for 
developing dementia remains controversial despite evidence of AD neuropathology in 
persons carrying a diagnosis of MCI at the time of death.16,17 Back transitions—recovery 
from a worse cognitive state to a better one—are likely heterogeneous in origin and may 
be explained by misclassification of either the MCI or normal state, inter-study and inter-
clinician differences in application of diagnostic criteria, within-patient variability due to 
medical illness or psychosocial factors, or resistance to cognitive decline due to cognitive 
reserve.18-21    
There has been considerable effort to refine diagnostic criteria, separate MCI into 
amnestic and non-amnestic subtypes, and identify the underlying etiologies of MCI.10,22-25 
Diagnosis of MCI due to AD, for example, may include assessment of biomarkers to 
determine underlying etiology.25 Prevalence of MCI is estimated at between 3% and 19% 
of adults over age 65.9 
The disease processes that lead to dementia are, in general, continuous, but it is 
not possible to observe individuals continuously over the many years necessary for 
dementia to occur. Rather, longitudinal studies of aging and dementia typically assess 
individuals’ cognitive and physical status annually, thus producing discrete rather than 
continuous units of observation. At each assessment, the clinical status of the 
individual—normal cognition, MCI, or dementia—may be determined. Additionally, 
individuals may die or dropout of the study before a dementia occurs. 
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Familiar modeling tools, such as survival analysis, may be an intuitive choice for 
the analysis of these longitudinal data, but they have significant limitations. Traditional 
survival analysis methods, while capable of handling censored data, generally assume 
that the censoring mechanism is independent of the outcome of interest.  However, in 
prospective cohort studies that enroll cognitively normal older participants and follow 
them over time with the goal of observing incident dementias, the censoring mechanism 
is never independent of the outcome of interest. Volunteers for such studies, which often 
require considerable time and effort from participants and may include invasive study 
procedures, are often healthier, more affluent, and better educated than their peers who do 
not enroll in such studies. Many participants will die without ever becoming demented, 
even when dementing brain diseases are present.  Moreover, participants who do begin to 
show signs of cognitive impairment may be more likely to drop out of the study before a 
dementia can be observed.  
Even when survival analysis techniques that do account for competing risks are 
employed, however, these methods are still limited in the sense that they do not allow for 
multiple outcomes of interest. Markov processes, however, have proven to be useful 
alternatives for modeling data from such longitudinal studies. The Markov chain models 
the probability of transition between any two temporally adjacent assessments, here 
called the “prior state” and the “current state,” versus remaining in or returning to a “base 
state.” Multistate Markov chains offer two principal advantages over traditional survival 
analysis:  (1) they are capable of handling intervening clinical states between normal 
cognition and dementia, and (2) they always account for competing risks.  
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Kryscio et al. (2006) carried out the first application of a multistate Markov chain 
to the study of incident dementia. Results based on data from the Biologically Resilient 
Adults in Neurological Studies (BRAiNS) cohort, a longitudinal study of aging and 
cognition at the University of Kentucky Alzheimer’s Disease Center (UK ADC), 
demonstrated that well established risk factors for dementia (i.e., age, education, family 
history of dementia, apolipoprotein ε-4 status) were also risk factors for transitions from 
normal cognition to transient MCI states.26 Kryscio et al.’s model was developed further 
by Salazar et al. (2007), who incorporated a shared random effect to account for the 
correlations among observations arising from the same participant.27  
Other applications of the Markov model in incident dementia research include 
Tyas et al. (2007), whose examination of data from the Nun Study suggested that factors 
that increase dementia risk do so by predisposing individuals to MCI rather than 
dementia directly.28 The Nun Study, unlike the BRAiNS cohort, includes participants 
who were already demented at enrollment. Yu et al. (2009) evaluated the effect of 
excluding these baseline dementias from the likelihood and concluded that doing so 
introduces significant bias into the results.29 Yu et al. (2010) derived absorption statistics 
for the model, i.e., the overall relative risk of absorption between competing absorbing 
states and the mean and variance of the number of assessments required before an 
individual with a particular risk factor profile reaches an absorbing state.30 Finally, Song 
et al. (2011), in an application to the Einstein Aging Study, studied the effect of including 
a scaling parameter, dependent on the prior observed state, with the subject-specific 
random effect.31 
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Each of the aforementioned applications of the Markov chain included MCI states 
that were defined solely by an individual’s performance on one or more cognitive tests; 
such MCI states are inherently unstable.32 MCI states defined by clinical criteria, 
however, are possible and would likely engender fewer back transitions to normal.10,24 
The purpose of this dissertation is to use multistate Markov models to assess the 
influence of risk factors on transitions from normal cognition to test-based and clinical 
forms of MCI, dementia, or death without dementia in a group of participants drawn from 
the BRAiNS longitudinal cohort.  
The chapters that follow present studies into the nature of test-based and clinical 
MCI states, self-reported head injury as a risk factor for MCI and dementia, and the 
influence of prior states in the chain through the incorporation of a prior state-dependent 
scaling parameter with the shared random effect and specifying the effect of age as prior-
state dependent. In Chapter Two, “Mild cognitive impairment: statistical models of 
transition using longitudinal clinical data,” earlier research that applied Markov models to 
longitudinal data from the BRAiNS cohort is expanded by including a clinically 
determined, quasi-absorbing MCI state as a state in the model. The major finding from 
this study is that in the BRAiNS cohort, once an individual has entered the clinically 
determined MCI state they do not back transition to less impaired states, i.e., it is a true 
disease state.  
Results presented in Chapter Three, “Self-reported head injury and risk of late-life 
impairment and AD pathology in an AD Center cohort” support previous findings that 
individuals who report a history head injury have an increased risks of cognitive 
impairment, dementia, and death without dementia. This study, the first to assess 
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neuropathological data from an observational study in relation to head injury status, also 
reveals an unexpected increase in AD-type pathology among men who reported head 
injuries, despite those injuries taking place many years before death.  
Chapter Four, “Prior-state dependence among random effects and beta 
coefficients significantly improves multistate Markov chain model fit” begins the process 
of exploring back transitions among test-based MCI states and normal cognition as a 
function of modeling strategy and state definitions. Major findings, limitations, and future 
research problems are discussed in Chapter Five, the conclusion to the dissertation.  
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CHAPTER TWO 
Mild cognitive impairment: statistical models of transition using longitudinal 
clinical data 
Abstract 
Mild cognitive impairment (MCI) refers to the clinical state between normal cognition 
and probable Alzheimer’s disease (AD), but persons diagnosed with MCI may progress 
to non-AD forms of dementia, remain MCI until death, or recover to normal cognition.  
Risk factors for these various clinical changes, which we term “transitions,” may provide 
targets for therapeutic interventions.  Therefore it is useful to develop new approaches to 
assess risk factors for these transitions.  Markov models have been used to investigate the 
transient nature of MCI represented by amnestic single-domain and mixed MCI states, 
where mixed MCI comprised all other MCI subtypes based on cognitive assessments.  
The purpose of this study is to expand this risk model by including a clinically 
determined MCI state as an outcome. Analyses show that several common risk factors 
play different roles in effecting transitions to MCI and dementia. Notably, APOE-4 
increases the risk of transition to clinical MCI but does not affect the risk for a final 
transition to dementia, and baseline hypertension decreases the risk of transition to 
dementia from clinical MCI. 
Introduction 
Mild cognitive impairment (MCI) often refers to the clinical condition between 
normal cognition and probable Alzheimer’s disease (AD).  However, persons diagnosed 
with MCI may progress to non-AD forms of dementia, remain MCI until death, and in 
some instances recover to a normal cognitive state.10,11,32 There has been considerable 
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effort to refine diagnostic criteria, separate MCI into amnestic and non-amnestic 
subtypes, and identify the underlying etiologies of MCI.10,22,23 However, whether MCI is 
a true precursor to dementia remains controversial13,33-35 despite evidence of AD 
neuropathology in amnestic MCI.16,17 This is due in part to the description of ‘back 
transitions’ (i.e., recovery to normal cognition) that have been reported in longitudinal 
studies.15,32,35,36 Although the long-term prognosis for such cases is unclear, patients with 
a Clinical Dementia Rating (CDR) global score of 0.5 often have AD pathology at 
autopsy regardless of back transitions to CDR global scores of 0.37 Back transitions are 
likely heterogeneous in origin and may be explained by misclassification of either the 
MCI or normal state, inter-clinician differences in application of diagnostic criteria, 
within-patient variability due to medical illness or psychosocial factors, or resistance to 
cognitive decline due to cognitive reserve.18-21    
In a previous study we investigated MCI as defined by cognitive test performance 
alone. Here, we have added a clinical consensus-based MCI state as defined by the 
Second International Work Group on MCI10 and operationalized by the National 
Alzheimer’s Coordinating Center (NACC).24,38 We now have sufficient data on this MCI 
state to assess it as risk factor for dementia. The purpose of this study is to describe our 
statistical model of longitudinal data in the context of studying MCI risks and to update 
our prior research with additional cognitive assessments and clinical diagnoses from a 
large longitudinal sample.  Over 54% of the sample subjects now have a terminating 
event (i.e., we have 35 additional dementias and 69 additional deaths) compared to the 
36% in the previous study.  These additional events provide increased power to detect 
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potential risks for transition including age, gender, education, APOE-4, family history of 
dementing illness, and baseline hypertension.   
Methods 
Subjects 
Subjects in the current study are from the Biologically Resilient Adults in 
Neurological Studies (BRAiNS) at the University of Kentucky’s Alzheimer’s Disease 
Center (UK ADC), a longitudinal cohort of 1,030 individuals with ongoing recruitment 
established in 1989.39,40 Participants consent to extensive annual cognitive and clinical 
examinations as well as brain donation upon death. Exclusion criteria include age less 
than 60 years, active infectious diseases, neurological disorders, psychiatric disorders, 
disabling medical disorders, and dementing illness. Subjects included in the current study 
(n=554) comprise those included in the previous report.26 All subjects were cognitively 
intact at study entry. All research activities were approved by the University of Kentucky 
Institutional Review Board. Each participant gave written informed consent. 
 Cognitive Assessments 
Annual cognitive test-based assessments taken on a cohort of initially cognitively 
normal subjects participating in the BRAiNS project are used to classify subjects into one 
of three states: normal, test-based amnestic MCI (aMCITB), or test-based mixed MCI 
(mMCITB) (Table 2.1). Classification of aMCITB and mMCITB has been described 
previously.26,41 Briefly, a classification of aMCITB results from a poor score (as defined 
below) on at least one measure of episodic memory measure (Table 2.1). A classification 
of mMCITB requires a poor score on at least one measure of language or executive 
function (Table 2.1) regardless of the aMCITB classification status. A poor score is 
10 
 
defined as at least 1.5 standard deviations (SD) below the age-adjusted mean, which is 
consistent with the Second International Working Group on MCI criteria;10 normative 
values were derived from the baseline evaluations of the entire normal cohort.  
Classification into clinical consensus-based MCI (MCICC) results from a diagnosis of 
MCI, which is determined according to the consensus guidelines on MCI developed by 
the Second International Working Group on MCI.10 A diagnosis of MCI requires: 
1. a cognitive complaint by the subject or informant, or evidence for longitudinal 
decline on cognitive test performance (at least 1.5 SD decline); 
2. generally intact global cognition; 
3. no or minimal functional impairment; 
4. not demented by DSM-IV criteria. 
Additionally, MCICC is restricted to those individuals for whom a neurodegenerative 
etiology is suspected. The NACC diagnostic criteria designate patients with cognitive 
impairments but without a presumed degenerative etiology as “Cognitive impairment, not 
MCI”.24 Diagnosis of MCICC is based on a consensus team review by the examining 
physicians, neuropsychologists, and the clinical research assistant administering the 
protocol.15 This MCICC designation is equivalent in most respects to the new “MCI-Core 
Clinical Criteria” as defined by the National Institute on Aging-Alzheimer’s Association 
Workgroup on Diagnostic Guidelines for Alzheimer’s Disease.25 The primary difference 
is that the new criteria allow the cognitive complaint in number one above to come from 
a skilled clinician rather than only the patient or informant. A dementia classification also 
results from a clinical consensus diagnosis of dementia (most often AD), which may be 
based on the dementia criteria of Diagnostic and Statistical Manual of Mental Disorders 
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Fourth Edition (DSM-IV),1  criteria of the Joint Working Group of the National Institute 
of the Neurologic and Communication Disorders and Stroke-AD and Related Disorders 
(NINCDS-ADRDA),42 NINDS-AIREN criteria for vascular dementia,43 and the 2005 
Dementia with Lewy bodies (DLB) Consortium revised criteria.44 A diagnosis of MCICC 
or dementia supersedes a classification of normal cognition, aMCITB or mMCITB in our 
model.  
Between their annual assessments subjects may die or become demented, and 
these states are treated as completely absorbing competing states. MCICC is treated as a 
quasi-absorbing state, as subjects do not move backward to a transient state (i.e., normal 
cognition, aMCITB, or mMCITB), but they may become demented or die. 
For 19 subjects, review of the longitudinal record revealed apparent back 
transitions from MCICC to normal: nine subjects were diagnosed with MCICC, reverted to 
normal, and then reconverted to MCICC, three of whom eventually became demented; six 
subjects had a single diagnosis of MCICC between several diagnoses of normal cognition 
on either side; and four subjects had a single diagnosis of MCICC at their initial evaluation 
following the UK ADC’s implementation of the NACC Uniform Data Set (UDS) 
cognitive and clinical testing protocol24,45 with all subsequent evaluations classified as 
normal. Review of each subject’s complete study history revealed in all cases that the 
apparent back transitions were the result of underlying medical conditions, conflicting 
data from informants, or misclassification. Given that there are differences in the medical 
comorbidities (e.g., hypothyroidism, B12 deficiency) that can mimic MCICC in both 
research and general clinic settings (cf., Reference 15), ‘treatable’ cases of MCICC were 
not considered to reflect neurodegenerative conditions.  Similarly, a single diagnosis of 
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‘normal’ in the midst of many years of MCICC diagnoses appears to reflect a temporary 
resolution of a neurodegenerative condition and so strains credulity. Therefore, in light of 
the available evidence, the six normal to MCICC to normal cases and the four MCICC to 
normal cases were reclassified as never having MCICC, though they still might be 
classified aMCITB or mMCITB, and the nine MCICC to normal to MCICC were reclassified 
as MCICC at every assessment after the first diagnosis of MCICC. 
Statistical Analysis 
The conditional distribution of the cognitive status at any assessment given the 
status at the prior assessment is assumed to have the Markov property. That is, the status 
at the current assessment depends only on the status at the prior assessment46 and 
possibly other risk factors. A multi-state Markov chain with three transient states (normal 
cognition, aMCITB, and mMCITB), one quasi-absorbing state (MCICC), and two absorbing 
states (death and dementia) was used to model the probability of maintaining the current 
state or moving to a different state at the next assessment (Figure 1). The Markov chain 
models the log-odds of transition between any two temporally adjacent assessments, here 
called the ‘prior state’ and the ‘current state,’ versus remaining in or returning to a ‘base 
state’ with a series of four random effects polytomous logistic regression models (i.e., 
one model for each transient state and one model for the quasi-absorbing state, MCIcc). 
The base state is normal cognition while a participant’s prior state is normal 
cognition, aMCITB, or mMCITB; once a participant has moved into MCICC the base state 
then becomes MCICC. The model is additive, which means in practice that although we 
assume the risk factors are independent of the prior state (i.e., the effect of sex, for 
example, is the same whether the prior state is normal cognition, aMCITB, or mMCITB; 
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there is no interaction between the covariates and the prior state), the estimated risk factor 
beta coefficients may depend on the base state. That is, the effect of sex, for example, 
may vary with respect to a base state of normal cognition versus a base state of MCICC. 
To account for within-subject correlations a normally distributed shared random effect 
due to Salazar et al. (2007)27 was included in the model using PROC NLMIXED in SAS 
9.2®. The Quasi-Newton method is used to maximize the likelihood function, which due 
to the presence of the shared random effect is an integral approximated by an adaptive 
Gaussian quadrature with one quadrature point.47,48 Transitions to MCICC and dementia 
states are assumed to have occurred on the date of assessment as modeling assumptions 
do not permit the inclusion of interval censoring-type approaches. The model ignores any 
transitions among the transient states between regularly scheduled assessments. Statistical 
significance was set at α = 0.05. 
 Covariates 
Covariates of interest include age at assessment (centered at 78, the sample 
median), sex (1 = female, 0 = male), education (two levels: ≤ 12 years, >12 years), 
presence (1) or absence (0) of any copies of the APOE-4 allele, presence (1) or absence 
(0) of family history of dementing illness among first degree relatives, and presence (1) 
or absence (0) of hypertension at study entry. Hypertension status at entry was derived 
from participant responses to the question, “Have you ever been told by a doctor or nurse 
that you have high blood pressure?” Use of medications was also recorded; however, 
reported use of an anti-hypertensive medication did not supersede a participant’s 
response of ‘No’ since anti-hypertensives are used to treat other illnesses. Also included 
as covariates (when the base state is normal cognition) are two indicator variables for (1 
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= yes, 0 = no) aMCITB and mMCITB; normal cognition is the reference category. Race 
was not included as a covariate because almost all of the included subjects (99%) are 
Caucasian.  
Results 
Study participants contribute an average of 10.8 annual assessments (median = 10 
assessments, mode = 10 assessments) with the average time between assessments at 
approximately 13 months (Table 2.2). Approximately 87% of subjects who reported 
hypertension at baseline also reported taking at least one anti-hypertensive medication, 
whereas 15% of those who reported no history of hypertension reported taking at least 
one anti-hypertensive medication.    
 One-step transitions 
Table 2.3 enumerates the one-step transitions associated with each arrow in 
Figure 2.1. The majority of transitions from aMCITB, which requires a poor score on a 
test of episodic memory, are back to normal cognition at the next visit (59.3%), and only 
4.4% are transitions to MCICC or dementia. Mixed MCI (mMCITB), which requires a poor 
score on a test of executive function or language, appears more predictive of underlying 
impairment with 43.8% remaining mMCITB and 7.1% transitioning to MCICC or dementia 
at the next visit. Entry into MCICC is a clear risk factor for transition to dementia since the 
majority of the transitions into the dementia state come from MCICC when compared to 
transitions into dementia from the other states. As previously stated, recovery from 
MCICC does not occur. We note that 13 of the 16 subjects who were MCICC and died 
without a dementia diagnosis have been autopsied. Of these, five had AD-type pathology 
insufficient for an AD diagnosis, two had mixed AD and vascular pathology, two had 
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mixed vascular pathology (one with Lewy bodies and one with hippocampal sclerosis), 
two had hippocampal sclerosis, one had Parkinson’s disease, and one had no 
histopathologic substrate for dementia (see also Reference 5). 
Risk Factors 
A number of risk factors alter the probability of transition to an MCI state 
(Table2.4). Older age increases the risk of movement into aMCITB (p = 0.0006) and 
mMCITB (p < 0.0001).  In addition, 12 years or less of education predicts transition to 
mMCITB (p = 0.0001) but not aMCITB. Family history of dementia ‘protects’ against 
transitions to mMCITB (p = 0.011), and female sex is protective against entry into aMCITB 
(p = 0.013). Classification as mMCITB at the prior assessment is predictive of remaining 
mMCITB rather than returning to normal at the next assessment (p < 0.0001). 
Demographic risk factors for transition to the MCICC state (versus remaining in or 
returning to a normal state) are older age (p < 0.0001), presence of at least one APOE-4 
allele (p = 0.0053), and high school education (12 years) or less (p = 0.007). 
Classification as either aMCITB or mMCITB at the prior assessment also increases the risk 
of transition to MCICC (p = 0.0041 for aMCITB, p < 0.0001 for mMCITB).  
In the absence of MCICC, risk factors for dementia include older age (p < 0.0001) 
and the presence of at least one APOE-4 allele (p = 0.0057) (Table 2.4).  A classification 
as mMCITB (p <0.0001) but not aMCITB at the prior assessment also increases the risk of 
transition to dementia at the next visit. Risk factors for transition to death without 
dementia include older age (p < 0.0001) and self-reported hypertension at study entry (p 
= 0.018).  
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Participants in this sample who transitioned from MCICC to dementia (n = 34) did 
so in an average of 2.5 ± 1.5 years (median = 2.2 years), and those who transitioned from 
MCICC to death without an intervening dementia (n = 16) did so in an average of 2.7 ± 
1.7 years (median = 3.4 years).  Those cases that remain in the MCICC state (n = 50) have 
carried the diagnosis for an average of 4.1 ± 2.4 years (median = 4.2 years). Once a 
transition to MCICC has occurred, only history of hypertension at study entry appears to 
influence further transitions to dementia, or death without dementia, versus remaining in 
the MCICC state (Table 2.5). A participant who reported baseline hypertension is more 
likely to remain MCICC (p = 0.037) than to convert to dementia at the next visit: the 
yearly transition rate to dementia for those with hypertension at baseline is approximately 
4.2% and 12.6% for those without hypertension at baseline. 
Discussion 
The addition of the MCICC state to the multi-state Markov chain confirms the 
utility of cognitive testing in predicting true underlying cognitive impairment. Entry into 
aMCITB and particularly mMCITB, both of which are determined solely by poor 
performance on cognitive assessment, increases the risk of a diagnosis of MCICC at the 
next visit versus returning to normal. These results highlight the importance of objective 
criteria in MCI diagnosis and emphasize the role of cognitive testing, particularly of 
language and executive function, in early detection. Notably, poor performance limited to 
tests of episodic memory (aMCITB) in this population can resolve to normal performance 
at the next annual assessment as much as 60% of the time and progress to MCIcc just 3% 
of the time (Table 2.3). Poor performance on tests of language and executive function is 
somewhat more stable, returning to normal performance at the next annual assessment 
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33% of the time. While there is no question that MCITB predicts MCIcc, these findings 
emphasize that clinicians who primarily rely on cognitive testing should obtain 
longitudinal follow-up before a diagnosis of MCI is given to the patient.50  
These findings reflect a novel analysis of risk factors for MCI and dementia based 
on the current NACC UDS criteria that are used across AD Centers in the United States24 
and so represent a standardized diagnostic system in contrast to earlier analyses of MCI 
risk factors.50,51 Further, the comparison of two different sets of MCI criteria (MCICC vs. 
MCITB) provides differing risk factors that could be of clinical use in patient care.  This is 
best highlighted in our group’s earlier comparison of patients diagnosed with MCI in a 
clinical research (i.e., the UK ADC BRAiNS cohort) as well as a memory clinic setting 
where only 9% of patients in the memory clinic had non-neurodegenerative causes for 
cognitive decline in contrast to 31% of the research clinic cases.15  
Risk factors for one-step transitions into MCICC include age, low education, prior 
classification as either aMCITB or mMCITB, and the presence of at least one APOE-4 
allele. APOE-4 is a known risk factor for AD, and although results for MCI have been 
mixed, a recent study of a nationally representative sample reported that APOE-4 was a 
reliable predictor of MCI versus normal cognition,52 and data from the Religious Orders 
Study reveal a 1.4 fold increased risk of MCI in persons with an APOE-4 allele.53 
It is clear that once an individual has transitioned to MCICC the risk of dementia 
increases dramatically. In this sample, 38.5% of individuals with MCICC have 
transitioned to dementia (at an estimated overall rate of 12.6% per year) compared to 
11.8% of individuals with no history of MCICC (at an estimated overall rate of 0.16% per 
year).  However, common risk factors for dementia (i.e., age, sex, education, family 
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history, and APOE-4) do not predict whether an individual will remain in MCICC or 
transition to dementia, or death without dementia, at the next visit. Similar results have 
been reported in studies that have examined risk factors for progression of cognitive 
impairment. Tschanz et al. (2011)54 noted in the Cache County cohort that while female 
sex and age at onset were predictive of decline in Mini-Mental State Exam (MMSE) 
scores, education was not related to rate of MMSE decline, and APOE-4 was related to 
earlier onset of impairment but not rate of MMSE decline. Fleisher et al. (2007)55 
reported that although APOE-4 did predict conversion from amnestic MCI to AD over a 
36-month interval, it did not improve the predictive accuracy of their model (which 
included only neuropsychological test scores). 
Participants who reported hypertension at baseline were significantly less likely to 
transition from MCICC to dementia at the next visit, which may indicate a primarily 
vascular rather than an AD or mixed AD and vascular etiology for MCICC in these 
patients. Several studies have shown brain white matter changes are associated with 
cognitive decline in aging56,57 and that vascular changes exacerbate the cognitive decline 
associated with AD.58,59 Hoffman and colleagues (2009)60 reported that autopsied 
subjects who took anti-hypertensive medications had significantly less Alzheimer-type 
pathology than either those with no history of hypertension or those with hypertension 
not treated by medication. However, the differences in risks for treated and untreated 
hypertension could not be assessed here due to the small number of cases of untreated 
hypertension in the sample.  
As with aMCITB, mMCITB, and MCICC, older age increases the probability of a 
transition to a dementia state. Baseline hypertension plays no role in transitions to 
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aMCITB, mMCITB, MCICC, or dementia (in the absence of MCICC), predicting only 
transitions to death (modeled as a competing risk for dementia). This result agrees with 
our previous research41 even after four additional years of follow-up, as well as with the 
results of a recent meta-analysis, which found no increased risk of incidence of AD for 
either persons with hypertension or those taking anti-hypertensive medications.61 We 
note that hypertension is a time-dependent risk factor as the participant’s status may 
change during the course of follow-up. Availability of these time-dependent data is 
limited for many of the subjects in this sample; the study protocol did not call for annual 
assessment of health history until the implementation of the UDS in 2005. 
All forms of MCI, and dementia as well, reflect a heterogeneous (and not 
completely understood) group of diseases including AD, hippocampal sclerosis, dementia 
with Lewy bodies, and vascular dementia.5,62 This heterogeneity may help explain the 
lack of significant predictors, other than baseline hypertension, from MCICC to dementia. 
We currently lack sufficient sample size to study these dementias as separate entities, but 
we have recently initiated work that will facilitate future research on which factors 
influence transitions into dementia subtypes. Similarly, MCICC is treated as a single entity 
here despite its well-documented heterogeneity63 because we lack sufficient sample size 
to study the individual subtypes, and it is quite possible that risk factors for transitions to 
each subtype are different.  
Limitations of the current study include that the final outcome for the many of the 
included subjects is unknown as they continue to be followed longitudinally. Additional 
follow-up may change the results observed here, though they have face validity. The 
generalizability of the results is also somewhat limited due to the sample’s demographic 
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and geographic homogeneity, which would not be replicated in a population-based 
sample, and the nature of the longitudinal study, which requires brain donation at death. 
The volunteers are highly motivated and highly educated, and the frequency of both 
family history of dementia and APOE-4 is higher than what would be observed in the 
general population. Biomarker data (i.e., blood, cerebrospinal fluid, and neuroimaging) 
are for the most part unavailable on these subjects, and studies that have investigated risk 
factors for transition from clinical MCI to dementia have largely been focused on 
biomarkers.64,65 Obtaining biomarkers is extremely expensive, however, and it has been 
reported that longitudinal neuropsychological testing data provides as good or better 
accuracy in predicting which clinical MCI cases will convert versus remain stable.66 
Nevertheless, the recently published criteria for the diagnosis of MCI due to AD make 
extensive use of biomarker data,25 and this modeling technique will allow us to 
incorporate these data as they become available in the future. 
Finally, a large portion of this University of Kentucky-based longitudinal cohort 
was not included in this study (n = 476). The decision to exclude all subjects not in the 
original study (see Reference 26) was due to the fact that the model’s power to detect 
risks is based on the number of events in the sample, not the number of subjects. The 
excluded subjects, who are relatively recent recruits with about four assessments on 
average, are unable to contribute events due to this abbreviated follow-up. Potential 
differences between included and excluded participants were assessed using standard 
parametric two-group comparisons. Included and excluded subjects compare favorably 
on distribution of sex, family history, APOE-4, history of hypertension at baseline, and 
time between assessments (data not shown). Although the excluded subjects were slightly 
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older at baseline the effect size is small (Cohen’s d = -0.05). Excluded subjects also have 
lower education (χ2 = 8.8, 2 df, p = 0.01). That the excluded subjects are slightly older 
and less educated reflects that recruitment goals were changed in 2005 in order to enroll 
older participants with lower education, and all of the included subjects in the present 
model were recruited prior to 2005. 
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Table 2.1. Criteria for state classification 
 
State Definition 
Normal 
cognition 
No cognitive test score more than 1.5 standard deviations (SD) below 
the age-adjusted mean; absence of MCICC or Dementia  (see below) 
Test-based 
amnestic MCI 
(aMCITB) 
At least one score more than 1.5 SD below the age-adjusted mean on 
the following measures of episodic memory: Wechsler Logical 
Memory, Benton Visual Retention Test (number correct or number of 
errors), a word list (Consortium to Establish a Registry in Alzheimer’s 
Disease word list or California Verbal Learning Test ), total learning 
score, delayed recall score, savings score, the maximum recalled minus 
delayed recall score 
Test-based 
mixed MCI 
(mMCITB) 
At least one score more than 1.5 SD below the age-adjusted mean on 
the following measures of language and executive function: phonemic 
or category verbal fluency, Boston Naming Test (15-item), Trail 
Making Tests A or B 
Clinical 
consensus-
based MCI 
(MCICC) 
A cognitive complaint by the subject or informant, or evidence for 
longitudinal decline on cognitive test performance (at least 1.5 SD 
decline); generally intact global cognition; no or minimal functional 
impairment; not demented by DSM-IV criteria; neurodegenerative 
etiology suspected 
Dementia 
Meets DSM-IV criteria for dementia; or NINCDS/ARDRA criteria for 
possible or probable AD; or NINDS-AIREN criteria for possible or 
probable vascular dementia; or DLB Consortium criteria for Lewy 
body disease 
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Table 2.2. BRAiNS subject characteristics (n = 554) 
 
Characteristic Summary 
Age at entry, y (mean ± SD) 72.7 ± 7.8 
Female, % 64.3 
Family history of dementia, % 41.3 
At least one APOE-4 allele, % 30.0 
> 12 years of education, % 88.1 
History of hypertension at entry, % 36.6 
Hypertension treated with medication, % 86.5 
Number of assessments (mean ± SD) 10.8 ± 4.5 
Time between assessments, y (mean ± 
SD) 
1.1 ± 0.4 
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Table 2.3. One-step transition matrix (number of assessments [% of prior visit state]) 
 
Prior visit 
Current visit 
Normal 
Amnestic  
MCITB 
Mixed 
 MCITB 
Clinical 
Consensus
MCI 
Dementia Death 
Normal 2192 
(68.3) 
478 
 (14.9) 
385  
(12.0) 
34  
(1.1) 
19  
(0.6) 
100 
 (3.1) 
Amnestic MCITB 448 
(59.3) 
148  
(19.6) 
108 
 (14.3) 
23  
(3.1) 
10 
 (1.3) 
18  
(2.4) 
Mixed MCITB 341 
(33.0) 
88  
(8.5) 
453 
 (43.8) 
47  
(4.5) 
27  
(2.6) 
79  
(7.6) 
Clinical Consensus 
MCI 
   101  
(66.9) 
34  
(22.5) 
16  
(10.6) 
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Table 2.4. Estimated odds ratios and 95% confidence intervals for one-step transitions to test-based amnestic MCI 
(aMCITB), test-based mixed MCI (mMCITB), or clinical consensus MCI (MCICC) versus the base state of normal 
cognition (bolding denotes statistical significance).  
 
Risk factor* 
aMCITB 
vs. Normal 
mMCITB  
vs. Normal 
MCICC  
vs. Normal 
Age 1.02 (1.01 – 1.04) 1.07 (1.05 – 1.08) 1.12 (1.09 – 1.15) 
Female sex (vs. male) 0.77 (0.62 – 0.95) 1.01 (0.82 – 1.24) 0.71 (0.46 – 1.09) 
Family history of dementia (yes vs. no) 0.81 (0.65 – 1.00) 0.76 (0.62 – 0.94) 1.04 (0.66 – 1.64) 
≥ one APOE-4 allele (vs. none) 1.04 (0.83 – 1.31) 1.12 (0.89 – 1.40) 1.89 (1.21 – 2.95) 
≤12 years of education (vs. >12 years) 1.24 (0.89 – 1.74) 1.79 (1.33 – 2.42) 2.20 (1.24 – 3.91) 
History of hypertension (yes vs. no) 0.95 (0.76 – 1.18) 1.04 (0.84 – 1.28) 0.79 (0.42 – 1.49) 
aMCITB at prior assessment (vs. normal) 1.15 (0.91 – 1.45) 1.00 (0.77 – 1.29) 2.28 (1.30 – 4.00) 
mMCITB at prior assessment (vs. normal) 0.76 (0.57 – 1.02) 4.51 (3.63 – 5.61) 4.80 (2.94 – 7.81) 
*As risk factors do not depend on the prior state, covariate effects are the same regardless of whether transitions occur 
from a prior state of normal cognition, aMCITB, or mMCITB. 
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Table 2.5. Estimated odds ratios and 95% confidence intervals for one-step transitions to 
dementia or death without dementia versus the base state of normal cognition or clinical 
consensus MCI (MCICC) (bolding denotes statistical significance).  
Risk factors* (Normal is base state; no 
history of MCIcc) 
Dementia  
vs. Normal 
Death  
vs. Normal 
Age 1.19 (1.14 – 1.24) 1.18 (1.15 – 1.21) 
Female sex (vs. male) 1.87 (0.95 – 3.68) 0.68 (0.49 – 0.95) 
Family history of dementia (yes vs. no) 1.66 (0.92 – 3.01) 0.82 (0.57 – 1.17) 
≥ one APOE-4 allele (vs. none) 2.33 (1.28 – 4.23) 0.97 (0.67 – 1.42) 
≤12 years of education (vs. >12 years) 0.75 (0.26 – 2.18) 1.33 (0.80 – 2.22) 
History of hypertension (yes vs. no) 0.79 (0.42 – 1.49) 1.49 (1.07 – 2.08) 
aMCITB at prior assessment (vs. normal) 1.85 (0.82 – 4.21) 0.64 (0.38 – 1.08) 
mMCITB at prior assessment (vs. normal) 4.90 (2.58 – 9.30) 2.67 (1.88 – 3.79) 
Risk factors (MCICC is base state) 
Dementia  
vs. MCICC 
Death  
vs. MCICC 
Age 1.05 (0.98 – 1.13) 1.03 (0.94 – 1.13) 
Female sex (vs. male) 1.75 (0.67 – 4.56) 1.15 (0.65 – 3.76) 
Family history of dementia (yes vs. no) 2.88 (0.95 – 8.72) 0.68 (0.15 – 3.03) 
≥ one APOE-4 allele (vs. none) 0.69 (0.22 – 2.16) 2.33 (0.61 – 8.90) 
≤12 years of education (vs. >12 years) 0.97 (0.27 – 3.46) 0.55 (0.10 – 2.99) 
History of hypertension (yes vs. no) 0.30 (0.10 – 0.93) 0.70 (0.20 – 2.47) 
*As risk factors depend only on the base state, covariate effects are in the top half of the 
table are the same whether transitions occur from a prior state of normal cognition, 
aMCITB, or mMCITB.   
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Figure 2.1. Flow diagram of transitions possible between subject visits. Normal 
cognition is the base state for transitions made from normal cognition, test-based 
amnestic MCI, and test-based mixed MCI; clinical MCI is the base state otherwise.  
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CHAPTER THREE 
 
Self-reported head injury and risk of cognitive impairment and Alzheimer’s-type 
pathology in a longitudinal study of aging and dementia 
 
Abstract 
Longitudinal studies of premorbid head injury and Alzheimer’s-type (AD) clinical 
dementia to date have been largely limited to antemortem clinical data. In the current 
study, clinical and neuropathological data from participants in a longitudinal study of 
aging and cognition (N = 649) were evaluated for the long-term clinical effects of self-
reported head injury using a multi-state Markov chain, a statistical model capable of 
handling intervening cognitive states between normal cognition and dementia, as well as 
competing risks for dementia (i.e., death without dementia and dropout without 
dementia). The effect of self-reported head injury on clinical state depends on age at 
assessment: for a one-year increase in age, the OR for transition to clinically diagnosed 
Mild Cognitive Impairment (MCICC ) for participants with a history of head injury is 1.21 
(95% CI: 1.15 – 3.56). Similarly, for a one-year increase in age, the OR for transition 
from MCICC to dementia for participants with head injury history is 1.34 (95% CI: 1.11 – 
1.61). We also find that self-reported head injury, without respect to age at assessment, is 
a significant risk for transition from a clinically unimpaired state to death ( 	= 1.54, 
95% CI: 1.12 – 2.13). These results support prior work identifying earlier onset and 
increased risk of cognitive impairment with head injury as well as increased risk of 
mortality associated with a history of head injury. Since over one-third of the cohort has 
come to autopsy (n = 238), we examined plaque and tangle counts from the neocortical 
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and medial temporal areas to determine whether a history of head injury is associated 
with increased AD-type pathological burden. The odds of having AD pathology sufficient 
for an AD diagnosis is significantly increased for men with a history of head injury ( = 
1.47, 95% CI: 1.03 – 2.09) but not for women ( = 1.18, 95% CI: 0.83 – 1.68), and 
MANCOVA shows that men with head injury by history have significantly higher mean 
diffuse and neuritic plaque counts in the neocortex and entorhinal cortex compared to 
men without. 
Introduction 
The factors that contribute to late-onset Alzheimer’s disease (AD) are at present 
incompletely understood, but the evidence strongly suggests they include genetics.67 
Apolipoprotein-E (APOE) ε4 alters beta-amyloid deposition in the brain such that even a 
single copy dramatically increases the risk of AD.  AD commonly occurs, however, in 
individuals without the ε4 allele. A meta-analysis of AD study populations reports an 
estimated 41% of AD cases (range 23-64%) are APOE-ε4 negative.68 Further, genetic 
risks may be modified by environmental factors. Non-genetic risk factors that have been 
reported include, but are not limited to, head trauma,69-71 cardiovascular disease and 
related risk factors,72 and education.73,74 These risk factors suggest possible therapeutic or 
preventive strategies.  
Since the first investigation into the association between head injury and 
dementia,75 the literature has been limited from the standpoint that none of the 
epidemiological studies of head injury and AD-type clinical dementia have used autopsy-
confirmed diagnosis of AD or examined neuropathological data. This is significant 
because an estimated 20-30% of cases clinically diagnosed with AD have dementia due 
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to another cause,76 and conversely, approximately 80% of individuals 
neuropathologically diagnosed with AD also have additional pathologies.77 The purpose 
of the current study is to re-examine the association between self-reported head injury, 
risk of clinical dementia, and AD pathology using data from participants with detailed 
longitudinal cognitive assessments, as well as a subset of participants with textured 
neuropathologic data, and statistical tools capable of handling competing dementia risks.  
Background 
Autopsy-based studies of head trauma have reported increases in the number of 
beta-amyloid precursor protein (βAPP) positive neurons in cases of isolated severe head 
injury compared to age-matched controls.78 Long-term increases in tau and beta-amyloid 
pathology have been noted in patients with a history of a single head injury sustained 
between 1 and 47 years prior to death.79 Both acute and chronic axonal injury, including 
accumulation of proteins associated with neurodegenerative disease, has been observed in 
individuals with a history of head injury.80-82  However, the etiological links have not 
been solidly established in terms of how the brain trauma manifests neuropathologically. 
Studies of chronic traumatic encephalopathy (CTE) have involved autopsy 
series.83 CTE implies a history of repeated brain injury and is a progressive illness 
characterized by deficits in motor skills, cognition, and increased psychiatric symptoms 
such as depression, irritability, and aggression.84 CTE pathology is marked by increased 
tau pathology, and in some cases, TAR DNA-binding protein 4383 with or without diffuse 
beta-amyloid deposits.85 Thus, CTE has both clinical and neuropathological overlap with 
AD, but the two are also distinct diseases in terms of the severity, anatomical distribution, 
and other manifestations of brain pathology. 
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Epidemiological studies have yielded conflicting evidence. A meta-analysis of 15 
case-control studies found that although there was an overall increased odds of AD for 
those with a history of head injury with loss of consciousness (LOC) prior to the onset of 
AD (pooled odds ratio [ ] = 1.58 [95% CI: 1.21-2.06]), the odds of AD was increased 
for men (  = 2.29 [95% CI: 1.47-3.58]) but not for women (  = 0.91 [95% CI: 0.56-
1.47]).69 However, the severity of these injuries was not considered in the meta-analysis, 
and AD diagnosis was not autopsy-confirmed. Again, the imperfect concordance between 
clinical and pathological diagnoses may play a significant role. For example, in the case 
of diabetes and AD, studies that rely only on a clinical diagnosis of AD have reported 
findings largely opposite from those that consider the pathological diagnosis.67 
 Results from cohort studies have also been inconsistent (Table 3.1). Two large, 
prospective studies—The Rotterdam Study86  and The Adult Changes in Thought 
Study87—found no increased risk of dementia or AD associated with past head injury. 
Data from the smaller Betula study, by contrast, did reveal an increased AD risk for those 
participants with self-reported mild head injury but only for APOE-ε4 carriers.88 
 Retrospective cohort studies have tended to report that head injury is an 
independent risk factor for AD or decreases time to dementia onset. Plassman et al. 
(2000) reviewed military medical records and compared men with a history of closed 
head injury to those with an unrelated condition.70  Dementia, and AD specifically, was 
associated with both moderate and severe, but not mild, injury.  Retrospective review of 
medical records from Olmsted County, Minnesota residents who were treated for head 
trauma and were over age 40 years at the time of their last medical assessment showed no 
increased risk of AD or all-cause dementia.89 When time to onset was used as the 
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outcome, however, persons with head trauma developed AD a median eight years earlier 
than expected when compared to the age-based incidence of AD in the total county 
population.90 Similarly, a prospective cohort study of Manhattan residents found that 
after five years of follow-up, history of head injury with LOC within the preceding 30 
years was associated with earlier onset of AD, and the effect was stronger for those 
reporting a LOC of at least five minutes.71  
Methods 
Subjects 
Subjects of this study are volunteers from Biologically Resilient Adults in 
Neurological Studies (BRAiNS) at the University of Kentucky’s Alzheimer’s Disease 
Center, a longitudinal cohort of over 1,100 individuals established in 1989 with ongoing 
recruitment.40 The cohort comprises a convenience sample of older adults (age ≥ 60 
years) from central Kentucky.  Exclusion criteria for the BRAiNS cohort include 
prevalent neurological, psychiatric, and disabling medical disorders, as well as prevalent 
dementing illness (see Reference 40 for a detailed listing and explanation of recruitment 
and procedures). Subjects included in the current analysis (n = 649) were enrolled 
between 1989 and 2004, evaluated at least two times, and had APOE genotyping 
available. Participants are given annual cognitive and clinical assessments and donate 
their brains upon death. Participants who died and came to autopsy in the current study 
were included in a subset analysis. Of these, 17 cases were excluded because quantitative 
neuropathology data were unavailable. An additional 15 were excluded due to the 
presence of diffuse Lewy body disease, leaving 238/270 for study. All enrollees were 
cognitively normal at study entry, and all research activities were approved by the 
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University of Kentucky Institutional Review Board. Each participant provided written 
informed consent.  
Statistical Analysis 
Multistate Markov Chain  
To test the hypothesis that self-reported history of head injury promotes transition 
to impaired cognition, a multistate Markov chain was fit to the data. Multistate Markov 
chains are attractive for modeling cognitive decline,26,27,30,31,41,91 and they allow for the 
inclusion of competing risks for the outcome of interest (all-cause dementia) as 
participants who die or drop out before dementia onset may bias analyses.92,93 
Participants were classified into states at each assessment: (1) normal cognition, 
(2) test-based amnestic mild cognitive impairment (aMCITB), (3) test-based mixed MCI 
(mMCITB), (4) clinical consensus-based MCI (MCICC), (5) dementia (all-cause), (6) drop-
out without dementia, and (7) death without dementia. The classification method has 
been described in detail previously.26,91 Briefly, normal cognition represents the absence 
of any impairments on testing as well as the absence of any clinical diagnosis of MCI or 
dementia; test-based MCI indicates at least one observed score of at least 1.5 standard 
deviations below the expected score for age based on the performance of the entire 
normal cohort at baseline on tests of episodic memory (aMCITB) or language and 
executive function (mMCI TB); clinical consensus-based MCI (MCICC) indicates a 
diagnosis of MCI based on criteria used by the National Alzheimer’s Coordinating 
Center’s Uniform Data Set;24 and dementia indicates a clinical diagnosis of dementia 
based on DSM-IV criteria. 
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A multistate Markov chain with four transient states (normal cognition, aMCITB, 
mMCITB, and MCICC) and three absorbing states (death, dementia, and drop-out) was 
used (Figure 1). An individual may move freely among the transient states, but once an 
absorbing state is reached that individual’s follow-up ends for the purposes of the 
analysis; here records are truncated at the date of diagnosis. The model estimates the log-
odds of a one-step transition between any two adjacent assessments, here called the ‘prior 
state’ and the ‘current state,’ versus remaining in or returning to a ‘base state’ with a 
series of four polytomous logistic regression models (i.e., one model for each transient 
state). 
To account for within-subject correlation, random intercepts were included in the 
model as described in Abner et al. (2012)91 via PROC NLMIXED in SAS/STAT 9.3®.48 
Observed transitions are assumed to have occurred on the date of diagnosis, and the 
model ignores any transitions among the transient states between regularly scheduled 
assessments. A modified backwards selection procedure was used to fit the model (see 
Appendix A). Predictor variables stayed in the model only if they significantly affected 
any one-step transition probability.  
Risk Factors 
Presence or absence of a history of head injury was derived from participant 
responses to the intake interview questions, “Have you ever been knocked unconscious? 
If yes, how long were you unconscious, when did it happen, and how did it happen?” 
Participants who reported LOC of any duration, as well as participants who reported a 
diagnosis of concussion without LOC, were coded as positive for history of head injury. 
Where head injury was reported, approximate age at injury, LOC duration (< 5’, ≥ 5’), 
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and external cause of the injury were recorded. Participants who described their LOC as 
“a few moments,” “a few minutes,” “momentarily,” or whose LOC duration was not 
described (n = 6) were coded as < 5’.  
Additional injury data were derived from interviews conducted longitudinally by 
study clinicians. Thus, head injury was treated as a time-varying factor. Two-way 
interactions between head injury and sex as well as age were tested for inclusion in the 
model.95 A two-way interaction between head injury and APOE-ε4 could be not 
evaluated due to sample size limitations.  
Other risk factors of interest include age at assessment (centered at 79 years), sex, 
education (≤ 12 years, >12 years), APOE-ε4 carrier status (at least one ε4 allele vs. no ε4 
alleles), family history of dementia (first-degree relatives only), baseline hypertension 
(self-report), and baseline smoking history (never, 0 – 10 pack-years, 10 – 20 pack-years, 
20+ pack-years).  
Generalized Linear Regression 
Multivariate analysis of covariance (MANCOVA) was used to test the hypothesis 
that self-reported history of head injury leads to increased mean AD-type pathology in 
the neocortex and medial temporal lobe, both of which have been identified as sites with 
increased βAPP-positive neurons following head injury.78,95 MANCOVAs estimating the 
effect of head injury on mean diffuse (DPs) and neuritic plaque counts (NPs) as well as 
mean neurofibrillary tangle counts (NFTs) in the neocortex (frontal, temporal, parietal, 
and occipital regions) and medial temporal lobe (entorhinal cortex, amygdala, 
hippocampus CA1, and subiculum) were fit using PROC GLM in SAS/STAT 9.3®. 
Logistic regression was used to test the hypothesis that head injury increases the odds of 
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AD-positive pathology. All models included age at death and indicators for APOE-ε4 
status, male sex, presence of at least mild cerebral amyloid angiopathy (CAA) (which is 
associated with increased numbers of amyloid plaques), and whether clinical dementia 
was observed before death. Two-way interactions between head injury and age at death, 
APOE-ε4, and sex were also tested. Statistical significance for all analyses was set at α = 
0.05. 
Pathological Assessments 
AD-positive pathology refers to cases with Braak stage V or VI and with 
moderate or severely dense neuritic amyloid plaques according to CERAD criteria.96 
Neuropathological counting metrics and methods were exactly as described 
previously.62,97 
Results 
Clinical Data 
 
Study participants contributed an average of 10.4 longitudinal assessments 
(median = 10 assessments, range = 2-22 assessments), with the average time between 
assessments at approximately 13 months (Table 3.2). During the study period, 386 
(59.5%) participants transitioned to aMCITB at least one time, 398 (61.3%) transitioned to 
mMCITB at least one time, 129 (19.9%) transitioned to MCICC, 109 (16.8%) transitioned 
to dementia, 234 (36.1%) died without dementia, and 92 (14.2%) left the study without 
dementia. 
The majority of transitions from aMCITB are back to normal cognition at the next 
visit (57.6%), and only 3.7% are transitions to MCICC or dementia. Mixed MCI 
(mMCITB) appears more predictive of underlying disease with 45.7% remaining mMCITB 
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and 7.7% transitioning to MCICC or dementia at the next visit (Table 3.3). Participants 
who transitioned to dementia required an average of 10.4 ± 4.4 steps to do so (Table 3.4). 
The observed number of steps required for death without a dementia (9.8 ± 4.4) or 
dropout without a dementia (9.3 ± 4.5) underscores the importance of accounting for 
these competing events in modeling dementia risks.  
Self-reported head injury occurred in one-quarter the sample (166/649, 25.6%). 
Men (83/234, 35.5%) reported a significantly higher proportion of head injury than 
women (83/415, 20.0%): χ2 = 18.81, 1 df, p < 0.0001). The majority of head injuries 
reported were listed as having occurred prior to the baseline assessment (156/166, 
94.0%). In all but four cases, the head injury preceded the first diagnosis of dementia by 
at least 10 years. Most participants reported only a single instance of head injury, but 
some participants reported two (n = 15) or more (n = 3) instances. Men in this cohort tend 
to have reported injuries that result in LOC of at least five minutes more frequently than 
women (Table 3.5), though the difference is not statistically significant (31.3% vs. 
21.7%: χ2 = 1.98, 1 df, p = 0.16). When the external cause of the injury (Table 3.5) is 
taken into account, however, men do have significantly increased odds of LOC of at least 
five minutes compared to women (  = 2.55, 95% CI: 1.1 – 5.9). 
The interaction between head injury and sex was not significant and was not 
retained (see Table 3.6 for final fitted model). Head injury, without respect to age, was a 
significant risk for the one-step transition from a transient state to death without dementia 
( = 1.54, 95% CI: 1.12 – 2.13). The interaction between head injury and age was 
significant for the one-step transitions from normal cognition, aMCITB, or mMCITB to 
MCICC (p = 0.017) and the one-step transition from MCICC to dementia (p = 0.0069). For 
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a one-year increase in age, the  for transition from normal cognition, aMCITB, or 
mMCITB to MCICC for participants with a history of head injury is 1.21 (95% CI: 1.15 – 
3.56). Similarly, for a one-year increase in age, the  for transition from MCICC to 
dementia for participants with a history of head injury is 1.34 (95% CI: 1.11 – 1.61).  
Multistate Markov model results may also be used to estimate the expected 
number of one-step transitions required to reach the absorbing states.30 Table 3.7 shows 
the predicted number of one-step transitions a cognitively intact participant with a 
particular clinical profile would require before becoming demented or dying. Self-
reported head injury, in the absence of other risk factors, decreases the time to an 
eventual dementia by roughly 6 months. The risk factors presented here decrease the time 
to dementia in an additive fashion, and it is important to note that in all cases the 
predicted number of transitions to death without dementia and dropout without dementia 
(data not shown) are significantly reduced compared to time to dementia, which again 
underscores the necessity of accounting for these competing risks.  
 Finally, two sensitivity analyses were conducted to assess the effect of (1) 
excluding participants whose head injuries occurred after baseline (n = 10) and (2) 
excluding participants whose head injuries occurred less than 10 years prior to their first 
diagnosis of clinical dementia (n = 4). All three models produced a similar fit (to two 
decimal places), and conclusions did not change.  
Pathological Data 
Of the 238 included participants, 70 (29.4%) reported a history of head injury (36 
males [33% of autopsied men] and 34 females [26% of autopsied women]) (Table 3.8). 
The odds of having AD pathology sufficient for an AD diagnosis is significantly 
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increased for men with a history of head injury ( = 1.47, 95% CI: 1.03 – 2.09) but not 
for women ( = 1.18, 95% CI: 0.83 – 1.68).  
In the neocortex, men with a history of head injury have higher mean parietal and 
occipital DPs, and all neocortical areas show more NPs, than men without (p<0.05; 
Figure 3.3). Women with a history of head injury do not have significantly higher 
neocortical DPs or NPs than women (or men) without head injury (Figure 3.3). 
Additional analyses were performed to determine if age at injury or source of injury 
mitigated the observed sex by head injury interaction; the conclusions did not change 
(data not shown).  Mean neocortical NFTs were not associated with head injury history 
(data not shown).  
 Pathological burden in the medial temporal structures, except for the entorhinal 
cortex, was unaffected by history of head injury. Again, men who reported a history of 
head injury had significantly increased DPs (20.6 ± 2.3 vs. 13.4 ± 1.8, p = 0.0072) and 
NPs (3.8 ± 0.7 vs. 1.6 ± 0.6, p = 0.013) in the entorhinal cortex compared to men who did 
not. NFTs in the entorhinal cortex were unaffected (data not shown).  
Discussion 
 Clinical and neuropathological data from participants in a longitudinal study of 
aging and cognition (N = 649) were analyzed to assess the effects of self-reported head 
injury. Our results support prior work identifying increased risk of cognitive 
impairment97 and earlier onset of clinical dementia with head injury,71,89 as well as 
increased risk of mortality associated with a history of head injury.87  Although the six-
month reduction in time to dementia onset we report is much less than the eight years in 
the Olmstead County study,89 differences in study design, population, head injury case 
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definition, and clinical diagnosis could account for the discrepancy. We also found 
unexpected correlation between head injury, gender, and increased AD neuropathologic 
changes. 
The effect of head injury on dementia risk may be modified not only by age at 
injury and severity of injury (or injuries) but also by other factors including gender and 
APOE-ε4 status.94 We note that while a single injury of sufficient severity can increase 
the risk of manifesting clinical dementia, it does not necessarily follow that these events 
lead to the specific features of AD. In experimental studies (i.e., animal studies), 
however, evidence of long-term neurodegeneration was observed after a single head 
injury, and accelerated beta-amyloid peptide deposition and cognitive impairment was 
observed after repeated mild head injury.98 Thus, animal models have provided 
hypothesized mechanistic links between head injury and AD, and autopsy-based case 
series of head injury have also suggested a link between head injury and AD-promoting 
and AD-type pathology.79,82,99,100 
Detailed pathological data were available on over one-third of the study 
participants. History of self-reported head injury was associated with increased levels of 
amyloid plaque deposition in the neocortex and entorhinal cortex, as well as increased 
odds of AD pathology for men but not women, which supports prior clinical studies. 
Fleminger and colleagues (2003)69 posited that women may be protected from the 
deleterious effects of head injury by the presence of female sex hormones. Indeed, the 
women who came to autopsy in the current study were more likely to report two 
instances of LOC (6/34 vs. 1/36, p = 0.027, Fisher’s Exact test) and were more likely to 
have sustained a head injury after age 55 (16/34 vs. 7/36, p = 0.030, Fisher’s Exact test). 
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If AD pathology were more affected by more recent or frequent LOC, it should follow 
that the women and not the men would have elevated plaque counts in association with 
exposure to head injury.  
An alternative explanation is that male gender may be a proxy for severity, 
repetition, poor reporting, and particular mechanisms (e.g., contact sports) of brain injury. 
Men in our study tended to report injuries that led to LOC ≥ 5 minutes more often than 
women, which suggests that their injuries may have been more severe overall. Plassman 
and colleagues (2000) found increased risk of both all-cause dementia and AD for 
veterans with moderate and severe injuries but not mild injuries,70 and Schofield and 
colleagues (1997) found an increased risk of AD for participants who reported head 
injuries with LOC ≥ 5 minutes but not for < 5 minutes.71 Of the 36 autopsied men with a 
history of head injury, 13 (36%) reported sports and recreation as source of the injury, 
nine of which were identified as football or boxing. It may be that while the participant 
reported only one or two instances of head injury where LOC occurred, multiple 
instances of injury were actually experienced without LOC. Chronic effects of head 
injury may be due to lifetime cumulative exposure rather than an acute single event.101 
Recent data reveal an increased risk of AD for retired American football players, who are 
assumed to have been exposed to repeated blows to the head, relative to the general US 
population ( 	= 3.29, 95% CI: 1.55 – 7.95).102 
We note that for both genders, reported head trauma is usually quite remote even 
from study enrollment, in some cases occurring in infancy; however, these injuries could 
still affect the brain chronically.79 In addition to the influence of recall bias implicit to the 
study design, we note that participants in the current study are highly educated compared 
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to their peers nationally, with 65.7% having at least a Bachelor’s degree vs. 24.5% of 
those over age 60 years nationally.103 If, as Moretti and colleagues (2012) suggest, 
cognitive reserve is the best predictor of cognitive outcome and decline following head 
injury97, the participants in this study may have been less vulnerable to its effects. 
As for the neuropathology, head injury severity occurs along a spectrum, and 
coding such injuries dichotomously obscures relevant information.104 Recovery (and 
wound repair capacity of an individual) may also be graded on a continuum, and all these 
factors may influence the long-term sequelae of the injury.104 Future studies of head 
injury as a risk for dementia and AD should consider collecting detailed data on severity, 
anatomical location, post-traumatic amnesia, and receipt of treatment if possible. 
Despite the limitations inherent in the data, multiple studies have found that even 
a single reported occurrence of head injury is associated with increased risk of incident 
dementia years or decades later. Although such knowledge may not be useful to those 
individuals for whom head injury is not a modifiable risk factor (i.e., having already 
sustained one), it does underscore the necessity of taking proper precautions for those 
involved in professions and recreational activities where head injury is common. 
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Table 3.1. Summary of cohort studies of head injury and dementia 
 
Study Type* N Effect Estimate(s) for Dementia Risk Exposure Assessment 
Head 
Injury 
Prevalence 
Limitations 
Rotterdam 
Study (Mehta 
et al., 1999) 
P 6,645  = 0.8, 95% CI: 0.4-1.9 
Self-report to study 
physician 
12.0% 
2 years of follow-up, 
inclusion of younger 
adults (≤ 60 years), dx 
not autopsy-confirmed 
Adult 
Changes in 
Thought  
(Dams-
O'Connor et 
al., 2012) 
P 4,225 
Age at injury <25:  = 1.02, 95% CI: 0.87-1.20 
Age at injury 25-54:  = 1.04, 95% CI: 0.78-1.38
Age at injury 55+:  = 1.06, 95% CI: 0.81-1.39 
Self-report via 
structured interview 
by study personnel 
15.9% 
Dx not autopsy-
confirmed  
Plassman et 
al.  
(2000)  
R 1,776 
Mild injury:  = 0.76 95% CI: 0.18-3.29 
Moderate injury:  = 2.32, 95% CI: 1.04-5.17 
Severe injury:  = 4.51, 95% CI: 1.77-11.47  
Review of military 
medical records 
between 1944-1945 
n/a 
Head trauma sustained 
outside military service 
not accounted for, dx 
not autopsy confirmed 
Williams et 
al.  
(1991) ; 
Nemetz et al. 
(1999) 
R 1,283  = 1.2, 95% CI: 0.8-1.7; median onset 
shortened by 8 years (p = 0.0015) 
Review of Mayo 
Clinic medical records 
for cases with 
traumatic brain injury 
diagnosed between 
1935-1984 
n/a 
Head trauma not 
requiring hospital visit 
not captured, dx based 
on medical records not 
clinical interview, dx 
not autopsy- confirmed 
Sundstrӧm et 
al.  
(2007)  
P 543 
Without APOE-ε4:  = 0.9 (95% CI: 0.4-1.8) 
With APOE-ε4:  = 5.2 (95% CI: 2.0-14.0) 
Affirmative response 
to questionnaire item 
“have you ever 
suffered a head injury 
which required 
medical care?” 
13.1% 
Inclusion of younger 
adults (≤ 60 years), dx 
not autopsy-confirmed 
WHICAP 
(Schofield et 
al., 1997) 
P 271 
LOC <5 min:  = 1.7, 95% CI: 0.4-7.5 
LOC ≥5 min:  = 11.2, 95% CI: 2.3-59.8 
Self-report via 
structured risk factor 
interview at baseline 
and during a one-time 
physician interview 
10.0% 
Few participants with 
head injury in the 
sample (n = 27), dx not 
autopsy- confirmed 
*P = prospective, R = retrospective 
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Table 3.2. Characteristics of included participants from the BRAiNS cohort (n = 649); participants were enrolled in the study 
between 1989 and 2004. 
 
Characteristic Summary 
Age at entry, y (mean ± SD) 72.9 ± 7.4 
Female, % 63.9 
Family history of dementia, % 38.7 
At least one APOE-4 allele, % 30.4 
> 12 years of education, % 86.9 
History of hypertension at entry, % 38.2 
Smoking history at entry, %  
   Never smoked 49.2 
   >0 – 10 pack-years 10.3 
   10 – 20 pack-years 8.3 
   More than 20 pack-years 32.2 
History of head injury, % 25.6 
Number of assessments (mean ± SD) 10.3 ± 4.7 
Time between assessments, y (mean ± SD) 1.1 ± 0.3 
 
 
 
 
 
 
 
 
45 
 
4
5
 
 
Table 3.3. One-step transition matrix (number of assessments [% of prior visit state]); total subjects = 649 
Prior state 
Current state 
Normal 
Amnestic 
MCITB 
Mixed 
 MCITB 
MCICC Dementia Dropout Death
Normal 
2634 
(69.1) 
524 
(13.8) 
464 
(12.2) 
40  
(1.1) 
15 
(0.4) 
33 
(0.9) 
101 
(2.7) 
Amnestic MCITB 
497 
(57.6) 
172  
(19.9) 
129 
(15.0) 
23 
(2.7) 
9  
(1.0) 
13  
(1.5) 
20 
(2.3) 
Mixed MCITB 
404 
(30.7) 
97 
(7.4) 
601 
(45.7) 
66 
(5.0) 
35 
(2.7) 
30 
(2.3) 
80 
(6.2) 
MCICC 
   154 
(61.4) 
50  
(19.9) 
16 
(6.4) 
31 
(12.4)
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Table 3.4. Mean number of assessments made given last observed state and history of head injury 
 
 
All Subjects  
(N = 649) 
Head Injury 
(N = 166) 
No Head Injury  
(N = 483) 
Last Observed 
State 
n 
Assessments
(mean ± SD) 
n 
Assessments 
(mean ± SD) 
n 
Assessments 
(mean ± SD) 
Normal 
 
139 12.2 ± 4.0 28 12.8 ± 4.6 111 12.1 ± 3.9 
Amnestic 
MCITB 
 
7 12.3 ± 3.0 2 11.5 ± 0.7 5 12.6 ± 3.6 
Mixed 
 MCITB 
 
36 12.3 ± 5.2 7 10.4 ± 4.0 29 12.7 ± 5.4 
MCICC 
 
32 12.2 ± 4.0 9 14.3 ± 4.9 23 11.3 ± 3.4 
Dementia 
 
109 10.4 ± 4.4 27 10.1 ± 4.8 82 10.5 ± 4.3 
Dropout 
without 
dementia 
 
92 9.3 ± 4.5 21 9.4 ± 4.7 71 9.3 ± 4.5 
Death 
 without 
dementia 
234 9.8 ± 4.4 72 9.7 ± 4.1 162 9.8 ± 4.5 
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Table 3.5. Reported sources of head injury by gender and loss of consciousness (LOC)*  
 
Source 
Men Women Total 
LOC < 5’ LOC ≥ 5’ LOC < 5’ LOC ≥ 5’ LOC < 5’ LOC ≥ 5’ 
Sports and 
recreation 
22 7 9 2 31 9 
Automobile 
accident 
9 10 22 8 31 18 
Fall 7 5 15 7 22 12 
Interpersonal 
violence 
5 2 2 0 7 2 
Other blow to the 
head** 
8 2 7 0 15 2 
Not described 8 1 12 2 20 3 
*Cell entries reflect number of unique participants reporting the source; **e.g., being struck by falling objects, striking head on 
ceilings or walls 
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Table 3.6. Multistate Markov chain results for risk factors affecting transitions from 
transient states (T: normal cognition, aMCITB, or mMCITB) 
Parameter Risk Comparison 
Odds 
Ratio 
95% Confidence 
Interval 
p 
T → aMCITB    
    Age 1-year difference 1.03 1.02-1.04 <0.0001
    Sex Female vs. Male 0.79 0.66-0.93 0.0056
    Prior = aMCITB aMCITB vs. Normal 1.27 1.03-1.58 0.0277
    Prior = mMCITB mMCITB vs. Normal 0.77 0.59-1.01 0.0561
T → mMCITB    
    Age 1-year difference 1.07 1.06-1.09 <0.0001
    Education ≤ 12 years vs. > 12 years 1.70 1.38-2.10 <0.0001
    Prior = aMCITB aMCITB vs. Normal 1.06 0.84-1.34 0.6473
    Prior = mMCITB mMCITB vs. Normal 4.78 3.93-5.81 <0.0001
T → MCICC    
    Family History Present vs. Absent 1.42 1.11-1.83 0.0063
    APOE-ε4 Present vs. Absent 1.85 1.27-2.69 0.0014
      Age*Head Injury 
1-year difference in age when 
head injury is present 
1.21 1.15-3.56 0.0173
    Prior = aMCITB aMCITB vs. Normal 2.20 1.29-3.75 0.0038
    Prior = mMCITB mMCITB vs. Normal 5.86 3.81-9.00 <0.0001
T → Dementia    
    Age 1-year difference 1.18 1.13-1.23 <0.0001
    APOE-ε4 Present vs. Absent 2.58 1.52-4.38 0.0005
    Prior = aMCITB aMCITB vs. Normal 2.24 0.97-5.17 0.0596
    Prior = mMCITB mMCITB vs. Normal 7.65 4.08-14.34 <0.0001
T → Death     
    Age  1-year difference 1.19 1.16-1.22 <0.0001
    <1 – 10 pack-years <1 – 10 pack-years vs. Never 
smoked 
1.16 0.68-1.96 0.5914
    10 – 20 pack-years 10 – 20 pack-years vs. Never 
smoked 
1.20 0.65-2.22 0.5566
    ≥20 pack-years ≥20 pack-years vs. Never 
smoked 
2.05 1.49-2.83 <0.001
    Hypertension Present vs. Absent 1.46 1.08-1.96 0.0133
    Head Injury Present vs. Absent 1.54 1.12-2.13 0.0089
    Prior = aMCITB aMCITB vs. Normal 0.72 0.43-1.19 0.1980
    Prior = mMCITB mMCITB vs. Normal 2.60 1.85-3.64 <0.0001
T → Dropout    
    Age 1-year difference 1.06 1.02-1.09 0.0008
    Hypertension Present vs. Absent 1.90 1.20-3.00 0.0060
    Prior = aMCITB aMCITB vs. Normal 1.49 0.77-2.89 0.2324
    Prior = mMCITB mMCITB vs. Normal 1.98 1.77-2.22 <0.0001
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Table 3.6 Continued 
Parameter Risk Comparison 
Odds 
Ratio 
95% Confidence 
Interval 
p 
MCICC → Dementia     
   <1 – 10 pack-years <1 – 10 pack-years vs. Never 
smoked 
0.28 0.08-0.94 0.0388
    10 – 20 pack-years 10 – 20 pack-years vs. Never 
smoked 
0.27 0.07-1.09 0.0654
    ≥20 pack-years ≥20 pack-years vs. Never 
smoked 
0.31 0.13-0.71 0.0054
    Age*Head Injury 1-year difference in age when 
head injury is present 
1.34 1.11-1.61 0.0069
MCICC → Death  
    Age 1-year difference 1.12 1.04-1.20 0.0023
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Table 3.7. Head injury appears to lead at-risk individuals to transition into a dementia 
state faster than individuals without history of head injury. Shown are the average 
numbers of visits required for eventual transitions from cognitively normal to the 
absorbing states of dementia or death. 
 
Age Risk Factor Profile Dementia Death 
65 
None 13.8 3.3 
APOE-ε4 only 12.6 2.9 
Head injury only 13.3 3.1 
APOE-ε4 + Head injury 12.4 2.8 
APOE- ε4 + Head injury + Hx HTN + Hx ≥ 20 pack-
years smoking 
10.4 2.3 
85 
None 4.0 1.1 
APOE-ε4 only 3.5 0.9 
Head injury only 3.4 0.9 
APOE-ε4 + Head injury 3.0 0.7 
APOE- ε4 + Head injury + Hx HTN + Hx ≥ 20 pack-
years smoking 
2.4 0.5 
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Table 3.8. Characteristics of autopsied participants from the BRAiNS cohort by gender 
and history of lifetime head injury (n = 238) 
 
Sex Head 
Injury 
N Final 
MMSE* 
Age at death* APOE-ε4+ CAA+ 
Men 
Yes 36 26.4 ± 4.5 84.4 ± 6.9 22.2% 63.9% 
No 61 25.8 ± 4.3 86.9 ± 7.0 39.3% 54.1% 
Women 
Yes 34 27.5 ± 3.5 86.0 ± 8.0 20.6% 48.4% 
No 107 24.4 ± 7.7 87.1 ± 7.5 28.0% 52.3% 
*Results presented are mean ± SD 
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Figure 3.1. Participant flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total BRAiNS enrollment,
1989 ‐ 2012 
N=1099 
Enrolled prior to 2005 
n=740 
Missing APOE 
n=72 
Single evaluation only 
n=19 
Included in current study 
n=649 
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Figure 3.2. Flow diagram of transitions possible between subject visits. Normal 
cognition is the base state for transitions made from normal cognition, test-based 
amnestic MCI, and test-based mixed MCI; clinical MCI is the base state otherwise.  
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Figure 3.3. Estimated mean number of diffuse and neuritic neocortical plaque counts by region; whiskers are SEM (n = 238). 
The final MANCOVA models included main effects for age at death, clinical dementia status, APOE-ε4, CAA, and an 
interaction term and main effects for head injury (HI) and male gender.  
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CHAPTER FOUR 
Incorporating prior-state dependence among random effects and beta coefficients 
improves multistate Markov chain model fit: Application to the Biologically 
Resilient Adults in Neurological Studies cohort 
 
Abstract 
Identifying risk factors that promote specific transitions, perhaps especially back 
transitions, is desirable because they might suggest avenues for intervention. However, it 
is important to establish that such risk factors are not an artifact of methodology or 
misclassification. The current study represents the first portion of a larger project 
investigating the nature of back transitions, which occur when an individual moves from 
a more cognitively impaired state to a less cognitively impaired state. Longitudinal 
clinical data from 649 participants in the BRAiNS cohort were used to investigate the 
scaling of subject-specific random effects based on the prior observed state as described 
in Song et al. (2011), who used data from the Einstein Aging Study (EAS), which has 
more subjects than the BRAiNS dataset but less follow-up per subject. Where the 833 
EAS subjects contributed 2,152 transitions, the 649 BRAiNS subjects contributed 6,240 
transitions. We evaluated four multistate Markov chain models –two models specified the 
effect of age as dependent on the prior state and two models included prior-state 
dependent scaling parameters—in order to investigate the influence of model architecture 
on model fit and parameter estimation. Both strategies improved fit as determined by 
likelihood ratio tests, although at a cost of extra parameters, which is a concern for 
models that already tend to have a high number of parameters that must be estimated as 
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more parameters require more data. Finally, this study provides evidence that the 
magnitude of the effect of age on study outcomes, like dropout, changes as clinical status 
changes. While increasing age does not appear to lead cognitively normal individuals to 
discontinue their study participation, increasing age does promote dropout among 
participants with non-amnestic memory impairments. For these participants, a one-year 
increase in age produces an odds ratio for dropping out of 1.08 (95% CI: 1.03-1.14). 
 
Introduction 
Alzheimer’s disease (AD) is thought to follow a chronic disease course with a 
lengthy preclinical phase that begins years before the onset of observable clinical 
symptoms.105 This preclinical phase is followed by a period of clinically detectable but 
relatively subtle cognitive impairment that is unaccompanied by functional impairment 
termed mild cognitive impairment (MCI) that typically lasts for several years.31 
Evaluation of risk factors for incident AD then, as well as estimation of disease 
progression rates through and/or including MCI, require a period of observation also 
lasting many years. Prospective cohort designs with multiple annual or biennial 
evaluations are a natural choice for such studies. 
While the course of AD is a continuous process, it is observed discretely over the 
study period. At each study visit a participant may be classified by where he or she falls 
along the continuum—for example, as cognitively normal, MCI, or demented. Multistate 
Markov chains (see Table 1 for definition of terms) are useful for modeling the 
movement of participants through transient states (normal cognition and forms of MCI) 
to absorbing states (dementia or death)26,27,30,31,91 and can identify risk factors for each 
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specific one-step transition defined in the data (see Figure 4.1). A first-order Markov 
chain estimates the probability of transition between clinical states at any two temporally 
adjacent assessments, here called the “prior state” and the “current state,” versus 
remaining in or returning to a “base state.” States may be either transient, where 
movement out of the state is permitted, or absorbing, where no further movement is 
permitted once a subject has entered the state.  
In addition to allowing for non-linear trajectories, analysis of longitudinal clinical 
data generally requires some method of addressing within-subject correlation among 
observations arising from the same subject. A normally distributed shared random effect 
(i.e., all observations from the same participant share a common random effect) due to 
Salazar et al. (2007)27 was used in prior applications of the multistate Markov chain to 
data from the Biologically Resilient Adults in Neurological Studies (BRAiNS) cohort.91  
It has been observed, however, that the inclusion of this shared random effect 
does not appreciably improve the fit of the model over a fixed effects only model.31 Song 
and colleagues (2011) proposed including prior state-dependent scaling parameters with 
the shared random effect to adjust for the variance of the random effects given the last 
observed state.31  Their model comprised four states: transient states normal cognition 
and memory impairment and absorbing states dementia and death. The purpose of this 
investigation is to evaluate the effect prior state-dependence—implemented through the 
scaling parameter and through specification of the effect of age as prior-state 
dependent—on model fit and parameter estimation when applied to the BRAiNS data. 
Methods 
Subjects 
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Subjects in this study are drawn from research volunteers in the BRAiNS cohort 
at the University of Kentucky’s Alzheimer’s Disease Center, a longitudinal cohort of 
approximately 1,100 individuals at least 60 years of age at study entry, established in 
1989 with ongoing recruitment.40 Exclusion criteria for the BRAiNS cohort include 
prevalent neurological disorders, psychiatric disorders, disabling medical disorders, and 
prevalent dementing illness (see Reference 40 for a detailed listing). Subjects included in 
the current analysis (n = 649) were all enrolled between 1989 and 2004, were evaluated at 
least two times, and had APOE genotyping available. Participants are given detailed 
annual cognitive and clinical assessments and donate their brains upon death. Annual 
assessments have been described in detail previously.40  All enrollees were clinically 
cognitively normal at study entry, and all research activities were approved by the 
University of Kentucky Institutional Review Board. Each participant provided written 
informed consent.  
States 
Participants were classified into states at each assessment: (1) normal cognition, 
(2) test-based amnestic mild cognitive impairment (aMCITB), (3) test-based mixed MCI 
(mMCITB), (4) clinical consensus-based MCI (MCICC), (5) dementia (all-cause), (6) drop-
out without dementia, and (7) death without dementia. The classification method has 
been described in detail previously.26,91 Briefly, normal cognition represents the absence 
of any impairments on testing as well as the absence of any clinical diagnosis of MCI or 
dementia; amnestic and mixed MCI are neuropsychological test-based and indicate at 
least one observed component score of at least 1.5 standard deviations below the 
expected score for age based on the performance of those members of the cohort assessed 
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as cognitively normal at baseline on tests of episodic memory (amnestic MCI) or 
language and executive function (mixed MCI)—mixed MCI supersedes amnestic MCI; 
clinical consensus-based MCI indicates a medical diagnosis of MCI based on criteria 
used by the National Alzheimer’s Coordinating Center’s Uniform Data Set;24 and 
dementia indicates a clinical diagnosis of dementia based on Diagnostic and Statistical 
Manual-IV (DSM-IV) criteria.1 In this cohort, back transitions from clinical MCI to 
normal cognition or test-based MCI were small in number (n = 19) and were judged to be 
the result of medical conditions (which preclude the diagnosis of clinical MCI based on 
our operational definition) or diagnostic misclassification. Such events were coded as 
described in Abner et al. (2012).91  
Model 
Let Yi = (yit1, …, yitni) be the vector representing the observed states (see Figure 
4.1) for the ith subject at the tni ordered assessments. Assuming the Markov property 
holds, we find the joint distribution of this vector by conditioning on yi1: f(yi|yi1) = f 
(yi2|yi1)·f (yi3|yi1, yi2) · · ·f(yitni|yi1, yi2, … ,yitni−1), which can be simplified as f(yi|yi1) = f 
(yi2|yi1)·f (yi3| yi2) · · ·f(yitni|yitni−1). Each term in the product is a one-step transition 
probability of moving from state s, the prior state, to state v, the current state. To simplify 
notation we define this probability, psv, as f (yiv|yis) = pyis,yiv = psv. 
The goal is to construct a model for these one-step transition probabilities, which 
may depend on covariates, some of which may be time-dependent, as well as random 
effects. To this end, let the prior state s be a transient state (i.e., normal [1], amnestic MCI 
[2], mixed MCI [3], or clinical MCI [4]) observed for subject i at the prior assessment and 
v be the state observed for subject i at the current assessment (v = 1, .., 7).   
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We assume the log-odds of transition may be modeled as  
        log[psv( |xiv, ui)/ps1( |xiv,ui)] = αsv + v
Txiv + ui1,  if s ∈ {1, 2, 3}, and 
        log[p4v( |xiv, ui)/p44( |xiv,ui)] = α4v + v
Txiv + ui2,  if s = 4 and v ≥ 4.        (1) 
Here  is the vector of alpha intercepts and beta coefficients when normal (state 1) is the 
base state,  is the vector of alpha intercepts and beta coefficients when clinical MCI 
(state 4) is the base state, xiv is the vector of covariates for the i
th subject observed at the 
current visit, and ui = (ui1, ui2) is the vector of random effects for the i
th subject. We 
assume ui is independently and identically distributed as bivariate normal: N2(0, ), where 
0 = (0, 0)T and   = 
1 1, 2
1, 2 2
var( ) cov( )
cov( ) var( )
i i i
i i i
u u u
u u u
 
 
 
. Given seven defined states (see Figure 
4.1), and  
7
sv iv i
1
| , 1
v
p

 θ x u  for any s ∈ {1, 2, 3}, we have  
psv( |xiv,ui) = exp{αsv + v
Txiv + ui1}/[1 + Σexp{αsh + h
Txih + ui1}] (2) 
where h = [2,…, 7] and “exp” indicates the term in braces is an exponent with Euler’s 
number as its base, and  
                       ps1( |xi1,ui) = 1/[1 + Σexp{αsh + βh
Txih + ui1}]                (3) 
Equations similar to (2) and (3) hold for p4v( |xiv,ui) and p44( |xi4,ui) respectively, where 
the sum is over h = 5,..,7. Given = ( ,	 ), the complete vector of alpha intercepts and 
beta coefficients, , i( | ) = sv ivp  x u  
    1/[1 + Σexp{αsh + βh
Txih + ui1}, if s ∈ {1, 2, 3}] and v = 1  
    exp{αsv + v
Txiv + ui1}/[1 + Σexp{αsh + h
Txih + ui1}], if s ∈ {1, 2, 3} and v > 1  
    1/[1 + Σexp{α4h + βh
Txih + ui2}], if s = 4 and v = 4 
    exp{α4v + v
Txiv + ui2}/[1 + Σexp{α4h + h
Txih + ui2}], if s = 4 and v > 4  
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 When the base state is normal (i.e., state 1), it is clear that larger values of ui1 lead to 
larger values for psv and smaller values for ps1 (see Equations 2 and 3) .  Thus, larger 
values of ui1 are associated with subjects who are more likely to make transitions away 
from the base state (here normal cognition). Because transitions from clinical MCI to 
normal do not occur here, a subject-specific random effect ui2 is needed when considering 
transitions from clinical MCI to dementia, death, or dropout. As with ui1, larger values of 
ui2 are associated with subjects who are more likely to make transitions away from the 
base state, clinical MCI. The random effects may be—but are not necessarily—correlated 
because they represent the same individual’s tendency to make transitions.  
Given yiti, the contribution of subject i to the likelihood can be expressed as 
follows: 
                              
,i (t-1) i t ii
it i
1
(  | , )
in
y y
t
p

 x u                         (4)  
where ni is the number of ordered observations for subject i. The marginal likelihood for 
the ith subject can be written as: 
,( 1)
2
1
( | , )d ( )
i
i t it ii i
n
y y it i i
t
p F


 x u u

              (5) 
where 2 represents the support for the bivariate normal distribution of ui, and F is its 
cumulative distribution function. When this integral is evaluated for all N subjects under 
study, the likelihood function is expressed as  
N
1
( | , )
i
L

 x u ,( 1)
2
1
( | , )d ( )
i
i t it ii i
n
y y it i i
t
p F


 x u u

 (6) 
This model can be implemented with PROC NLMIXED in SAS®, which uses an 
adaptive Gaussian quadrature to approximate the bivariate integral.  
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Song et al. (2011) propose that the model be revised such that the subject specific 
random effect is scaled based on the prior observed state:31 for example,  
log[psv(θ*|xiv,u i)|ps1(θ*|xiv,ui)] = α*sv + β*v
Txiv + λsui1, where θ* represents the vector of 
alpha intercepts and beta coefficients when normal (state 1) is the base state and the 
random effects are scaled based on the prior state. The scaling parameters, λ, improve the 
fit of the model by adjusting for the magnitude of the variance of the shared random 
effects as a function of the prior state. In other words, without the scaling parameter a 
subject’s tendency to make transitions to and away from the normal state is assumed to 
be constant regardless of the prior observed state, which may not be the case.  A unique λs 
is associated with transitions from each non-absorbing state si, in this case normal (s = 1), 
amnestic MCI (s = 2), mixed MCI (s = 3), and clinical MCI (s = 4). To avoid 
identifiability problems, λ1 is set equal to 1, and λ 2, λ 3, and λ 4 must be estimated.  
To assess the impact of the scaling parameter on model fit and beta parameter 
estimation, four proposed models were fit to the data: 
(1) Model 1: beta coefficients depend only on base state and current state; no scaling 
parameter: 
log[psv(θ|xiv,ui)/ps1(θ|xiv,ui)] = αsv + v
Txiv + ui1, where s ∈ {1, 2, 3}, and 
log[p4v( |xiv,ui)/p44( |xiv,ui)] = α4v + v
Txiv + ui2 , where s = 4 and v ≥ 4; 
(2) Model 2: beta coefficients depend only on base state and current state; scaling 
parameter: 
log[psv(θ*|xiv,u i)|ps1(θ*|xi,ui)] = α*sv + *v
Txiv + λsui1, where s ∈ {1, 2, 3}, and  
log[p4v( *|xiv,u i)|p44( *|xi,ui)] = α*4v + *v
Txiv + λ4ui2, where s = 4 and v ≥ 4; 
63 
 
(3) Model 3: Beta coefficients for age depends on prior state while all other beta 
coefficients depend only on current state; no scaling parameter: 
log[psv(θ|xiv,ui)|ps1(θ|xi,ui)] = αsv + β ∗ageiv + vTxiv + ui1, where s ∈ {1, 2, 3}, and 
log[p4v( |xiv,ui)/p44( |xiv,ui)] = α4v + β *ageiv + v
Txiv + ui2, where s = 4 and v ≥ 4; 
(4) Model 4: Beta coefficients for age depends on prior state while all other beta 
coefficients depend only on base and current states; scaling parameter: 
log[psv(θ*|xiv,ui)|ps1(θ*|xi,ui)] = α*sv + β
∗
*ageiv + β*v
Txiv + λsui1, where s ∈ {1, 2, 
3}, and 
log[p4v( *|xiv,ui)|p44( *|xi,ui)] = α*4v + β
∗
*ageiv + *v
Txiv + λ4ui2 , where s = 4 and 
v ≥ 4. 
Models 3 and 4, where the effect of age depends on the prior state, are motivated by the 
idea that if model fit can be improved by scaling the random effects based on the prior 
state, it might also be improved by making at least one of the beta coefficients depend on 
the prior state. Since the four models are nested, differences in fit between models can be 
assessed with likelihood ratio (LR) tests. 
Participant characteristics included in the model as independent variables are age 
at assessment, sex, years of education, APOE-ε4 status (present vs. absent), which are 
associated with risk of dementia,67,74,106,107 and self-reported baseline hypertension 
(present vs. absent), which is associated with risk of mortality.41 Statistical significance 
was set at α=0.05. 
Results 
 
The 649 BRAiNS participants in the current study (Table 4.2) made a total of 
6,240 one-step transitions (Table 4.2), including 433 terminating events (i.e., a transition 
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to an absorbing state), and were followed for 6,719 person-years. Among the transient 
states, the majority of transitions from amnestic MCI are back to normal cognition at the 
next visit (57.6%), and only 3.7% are transitions to clinical MCI or dementia. Mixed MCI 
appears more predictive of underlying disease with 45.7% remaining mixed MCI and 
7.7% transitioning to clinical MCI or dementia at the next visit (Table 4.3). Subjects who 
make transitions out of clinical MCI to an absorbing state do so in relatively few 
assessments, with 38.1% (44/118) reaching an absorbing state in one transition, and 
60.1% (71/118) reaching an absorbing state in two transitions.  
Model Convergence 
 
The simplest of the proposed models, Model 1, did not reach achieve convergence 
as specified. Efforts to achieve convergence included specifying initial parameter 
estimates based on results from a fixed effects only model, removing predictors to 
decrease the number of parameters being estimated, increasing the maximum number of 
iterations PROC NLMIXED attempts before terminating the likelihood optimization 
algorithm to 2000, and increasing the sample size with 246 additional subjects from the 
BRAiNS cohort. Given that an earlier version of the model that used only a single 
random effect to account for within-subject correlations without regard to the base state 
successfully converged,91 it would appear that convergence was most likely not achieved  
due to the inclusion of the base state-dependent random effects. Results from models that 
almost achieved convergence suggested that ui1 and ui2 were only weakly correlated 
(cov[u1,u2] ≈ -0.111) and that the estimated variance of ui2 was close to zero  (S 2 ≈ 
0.0197).  
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To investigate further the behavior of ui1 and ui2,the proposed likelihood function 
was split into two independent components where the first component modeled 
log[psv(θ|xiv,ui1)/ps1(θ|xiv,ui1)] = αsv + v
Txiv + ui1, where s ∈ {1, 2, 3}, and the second 
component modeled log[p4v( |xiv,ui2)/p44( |xiv,ui2)] = α4v + v
Txiv + ui2 , where s = 4 and v 
≥ 4. Note that this assumes ui1 and ui2 are independent (i.e., cov[ui1,ui2] = 0), and ui1 ~  
N(0, ) and ui2 ~  N(0, ). Random effect estimates produced by the latter model 
suggest that ui2 is unnecessary, with estimates for all subjects being zero or near zero 
depending on the number of specified quadrature points. Thus, ui2 and λ4 were taken to be 
zero for all subjects in all models. Since the lack of model convergence was due to the 
inclusion of ui2, its elimination allowed the full likelihood to be used rather than the split 
likelihood.  The results below were derived from the following models: 
(1) Model 1*: beta coefficients depend only on base state and current state; no scaling 
parameter: 
log[psv(θ|xiv,ui1)/ps1(θ|xiv,ui1)] = αsv + v
Txiv + ui1, where s ∈ {1, 2, 3}, and 
log[p4v( |xiv,ui1)/p44( |xiv,ui1)] = α4v + v
Txiv  , where s = 4 and v ≥ 4; 
(2) Model 2*: beta coefficients depend only on base state and current state; scaling 
parameter: 
log[psv(θ*|xiv,ui1)|ps1(θ*|xi,ui1)] = α*sv + v
Txiv + λsui1, where s ∈ {1, 2, 3}, and  
log[p4v( *|xiv,u i1)|p44( *|xi,ui1)] = α*4v + *v
Txiv, where s = 4 and v ≥ 4; 
(3) Model 3*: beta coefficients for age depends on prior state while all other beta 
coefficients depend only on current state; no scaling parameter: 
log[psv(θ|xiv,ui1)|ps1(θ|xi,ui1)] = αsv + β ∗ageiv + vTxiv + ui1, where s ∈ {1, 2, 3}, 
and,  
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log[p4v( |xiv,ui1)/p44( |xiv,ui1)] = α4v + β  *ageiv + v
Txiv, where s = 4 and v ≥ 4; 
(4) Model 4*: beta coefficients for age depends on prior state while all other beta 
coefficients depend only on base and current states; scaling parameter: 
log[psv(θ*|xiv,ui1)|ps1(θ*|xi,ui1)] = α*sv + β
∗
*ageiv + β*v
Txiv + λsui1, where s ∈ {1, 2, 
3}, and 
log[p4v( *|xiv,ui1)|p44( *|xi,ui1)] = α*4v + β
∗
*ageiv + *v
Txiv, where s = 4 and v ≥ 4. 
 
Model Comparisons 
Full Models 
There was perfect concordance between the nested full models regarding which 
parameters were significant predictors of transition, but while the beta coefficient and 
standard error estimates are stable in general, a small number of beta parameters vary 
dramatically (i.e., greater than 20% in magnitude) between the models with and without 
scaling parameters  (Tables 4.4 and 4.5). For Models 1* and 2*, percent change in beta 
parameter estimates ranges from -237.17 to 102.96 (median = 0.26), while percent 
change in standard errors ranges from -1.85 to 94.62 (median = 0). For Models 3* and 4*, 
percent change in beta parameter estimates ranges from -96.18 to 135.19 (median = 
0.34), while percent change in standard errors ranges from -10.67 to 8.91 (median = 0). 
 The addition of the scaling parameters to the subject-specific random effects does 
significantly improve fit (Table 4.6). Model 2* fits the data significantly better than 
Model 1* (LR test = 6, df = 2, p = 0.0497), and Model 4* fits the data significantly better 
than Model 3* (LR test = 6, df = 2, p = 0.0497). Model 4* has the best fit overall, as it is 
also significantly better than Model 2* (LR test = 22, df = 12, p = 0.038). 
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Reduced Models 
The full models were reduced using a modified backward selection procedure: all 
beta parameters with p-values higher than prespecified cut-points (0.25 at stage 1, 0.15 at 
stage 2, 0.10 at stage 3) were removed from the models and a LR test was conducted. If 
the reduced model fit as well as the full model, the reduced model was accepted. The next 
cut-point was used to further reduce the model, and the process was repeated until all beta 
parameters left in the model were significant at the 0.10 level. At this point the traditional 
backward selection procedure was used on the remaining beta parameters. 
As with the full models, fit in the reduced models is significantly improved with 
the addition of scaling parameters to the subject-specific random effects (Table 4.7). 
Here, Model 2* does not fit the data significantly better than Model 1* (LR test = 3, df = 
3, p = 0.40), but Model 4* still fits the data significantly better than Model 3* (LR test = 
6, df = 2, p = 0.0497). Model 4* again has the best fit overall, as it is also significantly 
better than Model 2* (LR test = 23, df = 10, p = 0.011). 
Reduced Models 1*and 2* agree on the significance of almost all beta parameters 
with the exception of education for transitions made from a transient state (normal, 
amnestic MCI, or mixed MCI) to dropout (Table 4.8). Percent change in parameters 
between Models 1* and 2* ranges from -46.14 to 26.71 (median = 0.00), and percent 
change in standard errors ranges from -3.57 to 274.77 (median = 0.19). Likewise, reduced 
Models 3* and 4* agree on the significance of all beta parameters with the exception of 
age for transitions made from mixed MCI to amnestic MCI (Table 4.9).  Percent change 
in parameters ranges from -21.64 to 14.73 (median = -0.11), and percent change in 
standard errors ranges from -3.57 to 5.54 (median = 0.12). 
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Prior state dependence 
Scaling Parameters 
In Model 2*, where the beta coefficients do not depend on the prior state, the 
effect of the amnestic state-dependent scaling parameter, λ2, is to reduce the magnitude of 
the subject-specific random effect, ui1, by about 38%. This speaks to the tendency of 
subjects in this dataset to return to the normal state following transitions to amnestic 
MCI, as 57.6% of all transitions from amnestic MCI (prior state) are to normal at the next 
assessment (current state). The effect of λ3, which scales ui1 for transitions made from 
mixed MCI, is to increase the magnitude of ui by about 9%. This speaks to the tendency 
of these subjects to continue to make transitions away from normal after entry into mixed 
MCI, as only 30.7% of such transitions are back to the normal state at the next 
assessment. In Model 4*, where the beta coefficients for age depend on the prior state, λ2 
and λ3 have similar but reduced estimates compared to Model 2*. Unlike in Model 2*, 
where λ3 increases the magnitude of ui1, here λ3 decreases the magnitude of ui1 by about 
8%. This suggests that treating the effect of age as prior-state dependent explains an 
additional portion of the variance accounted for by the random effects in Model 2*. 
Beta Parameters  
Results from Model 4* (Table 4.9) show that a one-year increase in age leads to a 
10.8% (95% CI: 5.9% –15.9%) increase in odds of transition to clinical MCI when the 
prior state is normal and to a 16.3% (95% CI: 11.5%-21.2%) increase in odds when the 
prior state is mixed MCI. More saliently, a one-year increase in age has no effect on the 
odds of dropping out when the prior state is normal but increases the odds of dropping 
out by 8.4% (95% CI: 2.8%-14.3%) when the prior state is mixed MCI. Other 
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explanatory variables may also be better specified as prior-state dependent, and more 
research is needed to determine which methods work best and in what circumstances 
since specifying prior-state dependence necessarily increases the number of parameters 
being estimated. 
Discussion 
Longitudinal clinical data from 649 participants in the UK ADC BRAiNS cohort 
were used to investigate the scaling of subject-specific random effects and the 
incorporation of beta parameters dependent on the prior observed state in a multistate 
Markov chain. We evaluated four models describing the timing and sequence of elderly 
participants’ transitions in relation to seven states: normal cognition, amnestic MCI (test-
based), mixed MCI (test-based), clinical MCI (diagnosis-based), dementia, death without 
dementia, and dropout without dementia. Two models specified the effect of age as 
independent of the prior state and two models included prior-state dependent scaling 
parameters. Previous applications of the multistate Markov chain to studies of aging and 
dementia have treated the effect of risk factors as both independent of26,27,30,91 and 
dependent on31 the prior state, although in the latter case this dependence was 
implemented through using the age at the prior visit to predict the current state. Results 
from the current study support treating the effect of age as prior-state dependent, which 
makes intuitive sense as well as producing a better fitting model.  
Achieving model convergence was a substantial difficulty in this study. There are 
several issues that could account for the lack of convergence, but two are most likely: 1) 
inadequate sample size, and 2) a misspecified model. Although the simplest model still 
failed to converge as initially specified with an increased sample size, the number of 
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subjects making transitions from a prior state of clinical MCI only increased from 118 to 
142. It might be the case that far more subjects are needed in order to estimate the 
random effects covariance matrix.  However, model misspecification is also plausible. 
PROC NLMIXED currently requires any random effect to be distributed normally and 
multiple random effects to be distributed as multivariate normal. While a normal 
distribution appears a reasonable choice for ui1, this is perhaps not the case for ui2. 
Further, while subject-specific effects may be meaningful in explaining an individual’s 
movement within the transition matrix prior to entering the clinical MCI state, they may 
be much less important thereafter. That is, once an individual has entered into a 
symptomatic clinical state, the effect of the disease is relatively uniform across 
individuals given their risk factors, and the random effect ui2 is truly unnecessary. More 
data are needed to answer these questions. 
When interpreting the prior-state dependent scaling parameter estimates, we 
should ask: (1) is the scaling parameter different from zero, and (2) is the scaling 
parameter different from one?  The first question is addressed by examining the 
associated p-value. Scaling parameters that are not different from zero should be 
removed, along with their random effects, from the model. Second, is the estimated 
scaling parameter different from one? This question is answered by examining the 
confidence interval around the estimate. If the scaling parameter is not different from 
one, as is the case here with λ3 in both Models 2* and 4*, then whether the extra 
parameter is necessary must be examined.  
While Song et al. found that the prior-state dependent scaling parameters improve 
model fit as determined by Akaike’s Information Criteria (AIC),108 only very modest 
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improvements in AIC were observed here.  The discrepancy may be partially explained 
by important differences in the models and datasets: Song et al. used data from the 
Einstein Aging Study (EAS), which has more subjects than the BRAiNS dataset but less 
follow-up per subject. Where the 833 EAS subjects contributed 2,152 transitions, the 649 
BRAiNS subjects contributed 6,240 transitions. Further, the EAS subjects experienced 
148 terminating events (i.e., dementia or death without dementia) while the BRAiNS 
subjects experienced 433 terminating events. The most important difference, however, is 
likely the complexity of the models. The EAS model has two transient and two absorbing 
states, while our model has four transient and three absorbing states. Where adding 
scaling parameters to the EAS model resulted in only one additional parameter, here it 
adds two. Finally, the improvement in fit reported by Song et al. was a 1.8% reduction in 
AIC. Thus, even in the simpler model, the relative improvement in AIC was small.  
We note, however, that expecting the AIC to decrease by adding parameters to the 
model is somewhat counterintuitive. Since AIC estimates model fit by adding a penalty 
of 2k to -2log-likelihood, where k is the number of model parameters, improving fit by 
adding parameters to the model will necessarily require that such improvements outweigh 
the penalty. Here, the addition of the two scaling parameters did significantly improve 
model fit as measured by LR tests, and the AIC did decrease in absolute terms despite the 
four-point penalty from the additional parameters. 
 Overall, specifying the effect of age as prior-state dependent had the most impact 
on model fit. Where adding the two random effects scaling parameters led to a six-point 
reduction in -2log-likelihood in Model 2* vs. Model 1* (Table 4.6), adding 12 parameters 
to make age prior-state dependent leads to a 22-point reduction in the -2log-likelihood in 
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Model 3* vs. Model 1*. When both the prior-state dependent scaling parameters and 
prior-state dependent beta coefficients for age are implemented (i.e., Model 4*), both -
2LogL and AIC are improved despite the addition of 14 parameters compared to Model 
1*.    
In the final reduced models, parameter estimates and standard errors were 
relatively stable between the models with and without random effect scaling parameters. 
The majority of parameter estimates were within 10%: 86.5% for Models 1* and 2*, 
91.7% for Models 3* and 4*. Likewise, the majority of standard error estimates were 
within 5%: 89.2% for Models 1* and 2*, 95.8% for Models 3* and 4. Of the four models 
investigated, Model 4*, where the effect of age depends on the prior state and there are 
scaling parameters for the random effects, is preferred.  
In addition to the criteria used to define clinical states, neuropsychological test 
data engender specific considerations.  Neuropsychological tests are typically 
administered to participants in longitudinal cohort studies to track cognitive performance 
over time. Measurements taken on the same participant over time may induce a learning 
effect, some study visits may be missed, and participants may drop out of the study or die 
before the clinical onset of dementia would be observed. Selection bias is an additional 
concern since participants in longitudinal studies, particularly those requiring brain 
donation upon death and/or invasive clinical procedures such as lumbar puncture, are 
inherently different from the general population. However, these issues are beyond the 
scope of this paper. 
 It is also important to note that individual performance over time need not be 
linear. Although increasing age is generally associated with some degree of decline in 
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cognitive performance,109 observed performance need not decline monotonically. 
Increased familiarity and practice due to repeated exposure to the instruments may lead to 
improving scores for many years before declines are observed.110 In addition to practice 
effects, cognitive performance may be influenced by transient comorbid medical 
conditions as well as psychosocial issues such as stress, anxiety, grief, and depression.15 
Thus, it is not unusual for a participant to back transition, i.e., appear cognitively 
impaired, even seriously so, at a given assessment and then unimpaired at the next 
assessment.  
Identifying risk factors that promote specific transitions, perhaps especially back 
transitions, is desirable because they might suggest avenues for intervention. However, it 
is important to establish that such risk factors are not an artifact of methodology or 
misclassification. In the current study, for example, classification into the test-based MCI 
states, amnestic and mixed, requires only a single poor score from among multiple tests. 
If the number of poor scores required for impairment was increased from one to two, or 
the definition of poor score changed from 1.5 SDs below the expected score to 2.0 SDs 
below the expected score, this would presumably affect the pattern of transitions 
observed and perhaps the associated risk factors.  
 The current study will serve as the basis for a larger project examining the 
influence of four factors on modeling back transitions from more impaired to less 
impaired states: (1) the effect subject-specific random effect scaling parameters, (2) the 
effect of prior-state dependent beta coefficients, (3) the effect of altering the definition of 
the test-based states to include at least two poor scores, and (4) the effect of altering the 
cut-point for impairment on the neuropsychological tests such that repeated 
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administrations are accounted for not only by the subject specific random effects but also 
by adjusting for practice effects. While sample size within the BRAiNS cohort is limited, 
data from five similar longitudinal cohorts will be soon be available for analysis via the 
NIA-funded study “Role of Impaired Cognitive States & Risk Factors in Conversion to 
Mixed Dementias” (R01AG038651-01A1).  
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Table 4.1. Summary of terms used to describe a multistate Markov chain 
Term Definition 
One-step 
transition 
 
Movement between or within states over two temporally adjacent 
assessments 
 
Current state 
 
The latter of two temporally adjacent states, e.g., state observed at 
time j 
 
Prior state 
 
The earlier of two temporally adjacent states, e.g., state observed at 
time j -1 
 
First-order 
 
A Markov chain that meets the assumption that the probability of 
observing the current state (j) depends on the prior state (j-1) and 
not, for example, the (j-2) or (j-3) state 
 
Transient state 
 
Any state from which a transition is possible 
 
Absorbing state 
 
Any state from which a transition is not possible 
 
Base state 
 
A transient state that has been designated as the reference category 
in a model 
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Table 4.2. Characteristics of included participants from the BRAiNS cohort (N=649); 
participants were enrolled in the study between 1989 and 2004. 
 
Characteristic Summary 
Age at entry, y (mean ± SD) 72.9 ± 7.4 
Age group, n (%)  
60 – 69 214 (33.0) 
70 – 79 307 (47.3) 
80 – 89  118 (18.2) 
≥ 90 10 (1.5) 
Female, % 63.9 
At least one APOE-4 allele, % 30.4 
Years of education, y (mean ± SD) 15.9 ± 2.5 
Education level, n (%)  
≤ 12 (High school or less) 85 (13.1) 
13 – 16 (College) 340 (52.4) 
≥ 17 (More than college) 224 (34.5) 
History of hypertension at entry, % 38.2 
Number of assessments (mean ± SD) 10.3 ± 4.7 
Time between assessments, y (mean ± SD) 1.1 ± 0.3 
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Table 4.3. Observed one-step transition matrix (number of assessments [% of prior visit 
state]); total subjects = 649. 
Prior state 
Current state 
Normal 
Amnestic 
MCI 
Mixed
 MCI 
Clinical 
MCI 
Dementia Dropout Death 
Normal 
2634 
(69.1) 
524 
(13.8) 
464 
(12.2) 
40  
(1.1) 
15 
(0.4) 
33 
(0.9) 
101 
(2.7) 
Amnestic 
MCI 
497 
(57.6) 
172 
(19.9) 
129 
(15.0) 
23 
(2.7) 
9  
(1.0) 
13  
(1.5) 
20 
(2.3) 
Mixed MCI 
404 
(30.7) 
97 
(7.4) 
601 
(45.7) 
66 
(5.0) 
35 
(2.7) 
30 
(2.3) 
80 
(6.2) 
Clinical MCI 
   154 
(61.4) 
50  
(19.9) 
16 
(6.4) 
31 
(12.4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7
8
 
Table 4.4. Full model fit comparison: all beta coefficients are independent of the prior state (T: normal cognition, amnestic 
MCI, or mixed MCI). 
Parameter 
No scaling parameters 
(Model 1*) 
Scaling parameters 
(Model 2*) Estimate
 % 
Change  
SE  
% 
Change Estimate SE p Estimate SE p 
T → Amnestic MCI         
Intercept (prior=normal) -0.213 0.398 0.59 -0.211 0.394 0.59 -0.94 -1.01 
Intercept (prior=amnestic) 0.00728 0.399 0.99 0.0691 0.395 0.86  849.18 -1.00 
Intercept (prior=mixed) -0.513 0.397 0.20 -0.553 0.395 0.16 7.80 -0.50 
Age (1-yr increment) 0.0285 0.00666 <0.0001 0.0285 0.00663 <0.0001 0.00 -0.45 
Sex (F vs. M) -0.268 0.108 0.013 -0.275 0.106 0.010 2.61 -1.85 
Baseline hypertension (Y vs. N) -0.0756 0.107 0.48 -0.0615 0.106 0.56 -18.65 -0.93 
APOE-ε4 (Y vs. N) -0.0756 0.114 0.51 -0.0839 0.113 0.46 10.98 -0.88 
Education (1-yr increment) -0.0608 0.0226 0.0073 -0.0608 0.0224 0.0067 0.00 -0.88 
T → Mixed MCI         
Intercept (prior=normal) 0.954 0.369 0.01 0.986 0.371 0.0081 3.35 0.54 
Intercept (prior=amnestic) 0.983 0.373 0.0087 1.0623 0.374 0.0047 8.07 0.27 
Intercept (prior=mixed) 2.441 0.359 <0.0001 2.434 0.362 <0.0001 -0.29 0.84 
Age (1-yr increment) 0.0748 0.00637 <0.0001 0.0756 0.00647 <0.0001 1.07 1.57 
Sex (F vs. M) -0.0135 0.104 0.90 -0.0274 0.105 0.79 102.96 0.96 
Baseline hypertension (Y vs. N) 0.0875 0.101 0.39 0.106 0.102 0.30 21.14 0.99 
APOE-ε4 (Y vs. N) 0.0724 0.108 0.50 0.0614 0.110 0.58 -15.19 1.85 
Education (1-yr increment) -0.157 0.0212 <0.0001 -0.159 0.0213 <0.0001 1.27 0.47 
T → Clinical MCI         
Intercept (prior=normal) -2.533 0.721 0.0005 -2.502 0.722 0.0006 -1.22 0.14 
Intercept (prior=amnestic) -1.786 0.725 0.014 -1.743 0.726 0.017 -2.41 0.14 
Intercept (prior=mixed) -0.840 0.695 0.23 -0.864 0.697 0.22 2.86 0.29 
Age (1-yr increment) 0.133 0.0140 <0.0001 0.134 0.0141 <0.0001 0.75 0.71 
Sex (F vs. M) -0.274 0.203 0.18 -0.276 0.203 0.17 0.73 0.00 
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Table 4.4. Continued 
Parameter 
No scaling parameters 
(Model 1*) 
Scaling parameters 
(Model 2*) 
Estimate
 % 
Change  
SE  
% 
Change 
Estimate SE p Estimate SE p   
Baseline hypertension (Y vs. N) 0.0210 0.203 0.92 0.0229 0.204 0.91 9.05 0.49 
APOE-ε4 (Y vs. N) 0.604 0.205 0.0033 0.584 0.206 0.0047 -3.31 0.49 
Education (1-yr increment) -0.0991 0.0411 0.016 -0.0995 0.0412 0.016 0.40 0.24 
T → Dementia         
Intercept (prior=normal) -3.520 1.0113 0.0005 -3.524 1.0124 0.0005 0.11 0.11 
Intercept (prior=amnestic) -2.782 1.0246 0.0068 -2.752 1.0234 0.0073 -1.08 -0.12 
Intercept (prior=mixed) -1.546 0.973 0.11 -1.603 0.975 0.10 3.69 0.21 
Age (1-yr increment) 0.164 0.0201 <0.0001 0.164 0.0202 <0.0001 0.00 0.50 
Sex (F vs. M) 0.385 0.316 0.22 0.371 0.615 0.24 -3.64 94.62 
Baseline hypertension (Y vs. N) -0.423 0.309 0.17 -0.389 0.308 0.208 -8.04 -0.32 
APOE-ε4 (Y vs. N) 0.985 0.283 0.0005 0.981 0.283 0.0006 -0.41 0.00 
Education (1-yr increment) -0.135 0.0577 0.019 -0.134 0.0578 0.021 -0.74 0.17 
T → Death         
Intercept (prior=normal) -2.551 0.623 <0.0001 -2.502 0.6230 <0.0001 -1.92 0.00 
Intercept (prior=amnestic) -2.890 0.647 <0.0001 -2.840 0.647 <0.0001 -1.73 0.00 
Intercept (prior=mixed) -1.608 0.609 0.0084 -1.607 0.610 0.0086 -0.06 0.16 
Age (1-yr increment) 0.173 0.0120 <0.0001 0.174 0.0121 <0.0001 0.58 0.83 
Sex (F vs. M) -0.408 0.171 0.017 -0.440 0.171 0.010 7.84 0.00 
Baseline hypertension (Y vs. N) 0.380 0.166 0.023 0.406 0.167 0.015 6.84 0.60 
APOE-ε4 (Y vs. N) -0.107 0.193 0.58 -0.103 0.194 0.60 -3.74 0.52 
Education (1-yr increment) -0.0427 0.0351 0.23 -0.0443 0.0352 0.209 3.75 0.28 
T → Dropout         
Intercept (prior=normal) -1.938 0.883 0.029 -1.967 0.884 0.026 1.50 0.11 
Intercept (prior=amnestic) -1.562 0.901 0.084 -1.503 0.900 0.095 -3.78 -0.11 
Intercept (prior=mixed) -0.805 0.853 0.346 -0.829 0.854 0.33 2.98 0.12 
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Table 4.4. Continued 
Parameter 
No scaling parameters 
(Model 1*) 
Scaling parameters 
(Model 2*) Estimate
 % 
Change  
SE  
% 
Change Estimate SE p Estimate SE p 
Age (1-yr increment) 0.0598 0.0166 0.0003 0.0599 0.0166 0.0003 0.17 0.00 
Sex (F vs. M) -0.0485 0.261 0.85 -0.0529 0.261 0.84 9.07 0.00 
Baseline hypertension (Y vs. N) 0.648 0.243 0.0078 0.656 0.242 0.007 1.23 -0.41 
APOE-ε4 (Y vs. N) 0.144 0.265 0.59 0.115 0.266 0.67 -20.14 0.38 
Education (1-yr increment) -0.155 0.0510 0.0025 -0.154 0.0510 0.0027 -0.65 0.00 
Clinical MCI → Dementia         
Intercept (prior=clinical MCI) -2.893 1.174 0.014 -2.909 1.173 0.013 0.55 -0.09 
Age (1-yr increment) 0.0296 0.0264 0.26 0.0299 0.0264 0.26 1.01 0.00 
Sex (F vs. M) 0.832 0.362 0.022 0.820 0.361 0.84 -1.44 -0.28 
Baseline hypertension (Y vs. N) -0.347 0.361 0.34 -0.311 0.360 0.387 -10.37 -0.28 
APOE-ε4 (Y vs. N) 0.751 0.360 0.038 0.741 0.360 0.040 -1.33 0.00 
Education (1-yr increment) 0.0593 0.0670 0.38 0.0604 0.0670 0.37 1.85 0.00 
Clinical MCI → Death         
Intercept (prior= clinical MCI) -4.503 1.502 0.0028 -4.542 1.503 0.0026 0.87 0.07 
Age (1-yr increment) 0.0777 0.0351 0.027 0.0779 0.0351 0.027 0.26 0.00 
Sex (F vs. M) 0.595 0.444 0.18 0.593 0.443 0.182 -0.34 -0.23 
Baseline hypertension (Y vs. N) 0.404 0.410 0.33 0.380 0.410 0.35 -5.94 0.00 
APOE-ε4 (Y vs. N) 0.280 0.451 0.54 0.269 0.451 0.551 -3.93 0.00 
Education (1-yr increment) 0.110 0.0835 0.19 0.114 0.0835 0.17 3.64 0.00 
Clinical MCI → Dropout         
Intercept (prior=clinical MCI) -2.124 1.584 0.18 -2.160 1.589 0.17 1.69 0.32 
Age (1-yr increment) 0.0287 0.0458 0.53 0.0289 0.0459 0.53 0.70 0.22 
Sex (F vs. M) -0.196 0.543 0.72 -0.210 0.545 0.70 7.14 0.37 
Baseline hypertension (Y vs. N) -0.920 0.662 0.16 -0.924 0.664 0.17 0.43 0.30 
APOE-ε4 (Y vs. N) 0.204 0.580 0.73 0.194 0.582 0.74 -4.90 0.34 
Education (1-yr increment) -0.00113 0.0932 0.99 0.00155 0.0934 0.99 -237.17 0.21 
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Table 4.4. Continued 
Parameter 
No scaling parameters 
(Model 1*) 
Scaling parameters 
(Model 2*) Estimate
 % 
Change  
SE  
% 
Change Estimate SE p Estimate SE p 
Scaling Parameters         
Prior=amnestic MCI 1.00 0.00 -- 0.619 0.172 0.0004 -- -- 
Prior=mixed MCI 1.00 0.00 -- 1.142 0.213 <0.0001 -- -- 
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Table 4.5. Full model fit comparison: age depends on prior state, all other beta coefficients are independent of the prior state. 
Parameter 
No scaling parameters 
(Model 3*) 
Scaling parameters 
(Model 4*) Estimate
 % 
Change  
SE  
% 
Change Estimate SE p Estimate SE p 
T → Amnestic MCI         
Intercept (prior=normal) -0.259 0.398 0.52 -0.241 0.395 0.54 -6.95 -0.75 
Intercept (prior=amnestic) -0.0368 0.399 0.93 0.0309 0.396 0.94 -183.97 -0.75 
Intercept (prior=mixed) -0.564 0.397 0.16 -0.572 0.394 0.15 1.42 -0.76 
Age (1-yr increment, 
prior=normal) 
0.0330 0.00781 <0.0001 0.0346 0.00802 <0.0001 4.85 2.69 
Age (1-yr increment,  
prior=amnestic MCI) 
0.0345 0.0136 0.011 0.0272 0.0132 0.040 -21.16 -2.94 
Age (1-yr increment, prior=mixed 
MCI) 
-0.00131 0.0160 0.94 -0.00005 0.0165 1.00 -96.18 3.13 
Sex (F vs. M) -0.268 0.108 0.013 -0.270 0.106 0.011 0.75 -1.85 
Baseline hypertension (Y vs. N) -0.0736 0.107 0.49 -0.0690 0.106 0.52 -6.25 -0.93 
APOE-ε4 (Y vs. N) -0.0772 0.114 0.50 -0.0722 0.114 0.53 -6.48 0.00 
Education (1-yr increment) -0.0577 0.0226 0.01 -0.0585 0.0224 0.0093 1.39 -0.88 
T → Mixed MCI         
Intercept (prior=normal) 0.920 0.368 0.013 0.938 0.370 0.012 1.96 0.54 
Intercept (prior=amnestic) 0.958 0.373 0.010 1.0246 0.374 0.0063 6.95 0.27 
Intercept (prior=mixed) 2.433 0.359 <0.0001 2.426 0.359 <0.0001 -0.29 0.00 
Age (1-yr increment, 
prior=normal) 
0.0855 0.00822 <0.001 0.0872 0.00844 <0.0001 
1.99 2.68 
Age (1-yr increment,  
prior=amnestic MCI) 
0.0756 0.0151 <0.0001 0.0675 0.0149 <0.0001 
-10.71 -1.32 
Age (1-yr increment, prior=mixed 
MCI) 
0.0580 0.0101 <0.0001 0.0595 0.0110 <0.0001 
2.59 8.91 
Sex (F vs. M) -0.0158 0.105 0.88 -0.0207 0.104 0.84 31.01 -0.95 
Baseline hypertension (Y vs. N) 0.0901 0.101 0.37 0.096 0.102 0.34 6.55 0.99 
APOE-ε4 (Y vs. N) 0.0691 0.108 0.52 0.0739 0.109 0.50 6.95 0.93 
Education (1-yr increment) -0.155 0.0211 <0.0001 -0.156 0.0213 <0.0001 0.65 0.95 
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Table 4.5. Continued 
Parameter 
No scaling parameters 
(Model 3*) 
Scaling parameters 
(Model 4*) Estimate
 % 
Change  
SE  
% 
Change Estimate SE p Estimate SE p 
T → Clinical MCI         
Intercept (prior=normal) -2.436 0.721 0.0008 -2.429 0.722 0.0008 -0.29 0.14 
Intercept (prior=amnestic) -1.725 0.732 0.0019 -1.675 0.732 0.022 -2.90 0.00 
Intercept (prior=mixed) -1.0188 0.702 0.15 -1.0324 0.702 0.14 1.33 0.00 
Age (1-yr increment,  
prior=normal) 
0.102 0.0228 <0.001 0.104 0.0230 <0.0001 1.96 0.88 
Age (1-yr increment,  
prior=amnestic MCI) 
0.116 0.0320 0.0003 0.108 0.0318 0.0007 -6.90 -0.62 
Age (1-yr increment,  
prior=mixed MCI) 
0.154 0.0212 <0.0001 0.155 0.0218 <0.0001 0.65 2.83 
Sex (F vs. M) -0.255 0.204 0.21 -0.264 0.203 0.19 3.53 -0.49 
Baseline hypertension (Y vs. N) -0.00540 0.204 0.98 -0.0127 0.204 0.95 135.19 0.00 
APOE-ε4 (Y vs. N) 0.608 0.205 0.0032 0.617 0.206 0.0028 1.48 0.49 
Education (1-yr increment) -0.0992 0.0412 0.016 -0.0990 0.0412 0.017 -0.20 0.00 
T → Dementia         
Intercept (prior=normal) -3.796 1.0445 0.0003 -3.789 1.0464 0.0003 -0.18 0.18 
Intercept (prior=amnestic) -3.0532 1.0918 0.0053 -2.982 1.0900 0.0064 -2.33 -0.16 
Intercept (prior=mixed) -1.612 0.976 0.10 -1.630 0.977 0.096 1.12 0.10 
Age (1-yr increment, 
prior=normal) 
0.186 0.0374 <0.0001 0.189 0.0375 <0.0001 
1.61 0.27 
Age (1-yr increment,  
prior=amnestic MCI) 
0.194 0.0535 0.0003 0.184 0.0530 0.0006 
-5.15 -0.93 
Age (1-yr increment,  
prior=mixed MCI) 
0.138 0.0268 <0.0001 0.140 0.0273 <0.0001 
1.45 1.87 
Sex (F vs. M) 0.367 0.315 0.24 0.357 0.315 0.26 -2.72 0.00 
Baseline hypertension (Y vs. N) -0.375 0.307 0.22 -0.388 0.309 0.21 3.47 0.65 
APOE-ε4 (Y vs. N) 1.010 0.282 0.0004 1.0253 0.283 0.0003 1.51 0.35 
Education (1-yr increment) -0.126 0.0580 0.030 -0.126 0.0581 0.030 0.00 0.17 
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Table 4.5. Continued 
Parameter 
No scaling parameters 
(Model 3*) 
Scaling parameters 
(Model 4*) Estimate
 % 
Change  
SE  
% 
Change Estimate SE p Estimate SE p 
T → Death         
Intercept (prior=normal) -2.611 0.626 <0.0001 -2.579 0.628 <0.0001 -1.23 0.32 
Intercept (prior=amnestic) -2.638 0.655 <0.0001 -2.576 0.656 <0.0001 -2.35 0.15 
Intercept (prior=mixed) -1.595 0.613 0.0095 -1.612 0.614 0.0089 1.07 0.16 
Age (1-yr increment, 
prior=normal) 
0.187 0.0160 <0.0001 0.188 0.0162 <0.0001 
0.53 1.25 
Age (1-yr increment,  
prior = amnestic MCI) 
0.123 0.0345 0.0004 0.116 0.0343 0.0008 
-5.69 -0.58 
Age (1-yr increment,  
prior=mixed MCI) 
0.162 0.0200 <0.0001 0.165 0.0207 <0.0001 
1.85 3.50 
Sex (F vs. M) -0.422 0.171 0.014 -0.426 0.171 0.013 0.95 0.00 
Baseline hypertension (Y vs. N) 0.386 0.166 0.020 0.406 0.167 0.015 5.18 0.60 
APOE-ε4 (Y vs. N) -0.110 0.193 0.57 -0.104 0.194 0.59 -5.45 0.52 
Education (1-yr increment) -0.0424 0.0351 0.23 -0.0440 0.0353 0.21 3.77 0.57 
T → Dropout         
Intercept (prior=normal) -2.0515 0.885 0.021 -2.0521 0.886 0.021 0.03 0.11 
Intercept (prior=amnestic) -1.625 0.905 0.073 -1.561 0.904 0.085 -3.94 -0.11 
Intercept (prior=mixed) -0.911 0.856 0.29 -0.927 0.857 0.28 1.76 0.12 
Age (1-yr increment,  
prior=normal) 
0.0180 0.0251 0.47 0.0193 0.0253 0.46 
7.22 0.79 
Age (1-yr increment,  
prior=amnestic MCI) 
0.0925 0.0403 0.022 0.0838 0.0398 0.036 
-9.41 -10.67 
Age (1-yr increment,  
prior=mixed MCI) 
0.0821 0.0271 0.0025 0.0836 0.0274 0.0024 
1.83 1.11 
Sex (F vs. M) -0.0483 0.261 0.85 -0.0459 0.261 0.86 -4.97 0.00 
Baseline hypertension (Y vs. N) 0.614 0.243 0.012 0.605 0.243 0.013 -1.47 0.00 
APOE-ε4 (Y vs. N) 0.121 0.267 0.65 0.130 0.267 0.63 7.44 0.00 
Education (1-yr increment) -0.151 0.0510 0.0032 -0.151 0.0510 0.0032 0.00 0.00 
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Table 4.5. Continued 
Parameter 
No scaling parameters 
(Model 3*) 
Scaling parameters 
(Model 4*) Estimate
 % 
Change  
SE  
% 
Change Estimate SE p Estimate SE p 
Clinical MCI → Dementia         
Intercept (prior=clinical MCI) -2.941 1.176 0.013 -2.935 1.175 0.013 -0.20 -0.09 
Age (1-yr increment) 0.0300 0.0264 0.26 0.0300 0.0264 0.26 0.00 0.00 
Sex (F vs. M) 0.829 0.361 0.022 0.829 0.361 0.022 0.00 0.00 
Baseline hypertension (Y vs. N) -0.295 0.359 0.41 -0.295 0.359 0.41 0.00 0.00 
APOE-ε4 (Y vs. N) 0.750 0.360 0.037 0.749 0.360 0.038 -0.13 0.00 
Education (1-yr increment) 0.0612 0.0671 0.36 0.0609 0.0671 0.36 -0.49 0.00 
Clinical MCI → Death         
Intercept (prior=clinical MCI) -4.611 1.511 0.0024 -4.601 1.510 0.0024 -0.22 -0.07 
Age (1-yr increment) 0.0781 0.0352 0.027 0.0781 0.0352 0.027 0.00 0.00 
Sex (F vs. M) 0.594 0.444 0.18 0.594 0.444 0.18 0.00 0.00 
Baseline hypertension (Y vs. N) 0.371 0.412 0.37 0.371 0.412 0.37 0.00 0.00 
APOE-ε4 (Y vs. N) 0.270 0.453 0.55 0.268 0.453 0.55 -0.74 0.00 
Education (1-yr increment) 0.118 0.0834 0.16 0.117 0.0839 0.16 -0.85 0.60 
Clinical MCI → Dropout         
Intercept (prior=clinical MCI) -2.204 1.593 0.17 -2.199 1.592 0.17 -0.23 -0.06 
Age (1-yr increment) 0.0293 0.0459 0.52 0.0294 0.0459 0.52 0.34 0.00 
Sex (F vs. M) -0.207 0.545 0.71 -0.212 0.545 0.70 2.42 0.00 
Baseline hypertension (Y vs. N) -0.919 0.663 0.17 -0.924 0.664 0.16 0.54 0.15 
APOE-ε4 (Y vs. N) 0.196 0.582 0.74 0.193 0.582 0.74 -1.53 0.00 
Education (1-yr increment) 0.00389 0.0936 0.97 0.00379 0.0936 0.97 -2.57 0.00 
Scaling Parameters         
Prior = amnestic MCI 1.00 0.00 -- 0.568 0.173 0.0011 -- -- 
Prior = mixed MCI 1.00 0.00 -- 1.00520 0.218 <0.0001 -- -- 
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Table 4.6. Full model characteristics. 
 
Betas independent of 
prior state 
Beta for age depends on 
prior state 
Fit statistics 
No scaling 
parameters
(Model 1*) 
Scaling 
parameters
(Model 2*) 
No scaling 
parameters 
(Model 3*) 
Scaling 
parameters
(Model 4*) 
-2LogL 13303 13297 13281 13275 
AIC 13437 13435 13439 13437 
AICC 13439 13437 13441 13439 
BIC 13737 13744 13792 13800 
Parameters 67 69 79 81 
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Table 4.7. Reduced model characteristics. 
 
Betas independent of 
prior state 
Beta for age depends on 
prior state 
Fit statistics 
No scaling 
parameters
(Model 1*) 
Scaling 
parameters
(Model 2*) 
No scaling 
parameters 
(Model 3*) 
Scaling 
parameters
(Model 4*) 
-2LogL 13333 13330 13313 13307 
AIC 13407 13410 13409 13407 
AICC 13407 13410 13409 13408 
BIC 13573 13589 13624 13631 
Parameters 37 40 48 50 
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Table 4.8. Reduced model fit comparison: all beta coefficients are independent of the prior state (T: normal cognition, 
amnestic MCI, or mixed MCI). 
 
Parameter 
No scaling parameters 
(Model 1*) 
Scaling parameters 
(Model 2*) Estimate
 % 
Change  
SE  
% Change Estimate SE p Estimate SE p 
T → Amnestic MCI         
Intercept (prior = normal) -1.266 0.0826 <0.0001 -1.283 0.0824 <0.0001 1.34 -0.24 
Intercept (prior = amnestic) -1.0484 0.112 <0.0001 -0.992 0.108 <0.0001 -5.38 -3.57 
Intercept (prior = mixed) -1.562 0.136 <0.0001 -1.584 0.141 <0.0001 1.41 3.68 
Age (1-yr increment) 0.0294 0.00666 <0.0001 0.0286 0.00659 <0.0001 -2.72 -1.05 
Sex (F vs. M) -0.211 0.0885 0.018 -0.203 0.0876 0.021 -3.79 -1.02 
T → Mixed MCI         
Intercept (prior = normal) 0.308 0.264 0.25 0.329 0.267 0.22 6.82 1.14 
Intercept (prior = amnestic) 0.322 0.278 0.25 0.408 0.280 0.15 26.71 0.72 
Intercept (prior = mixed) 1.788 0.263 <0.0001 1.803 0.267 <0.0001 0.84 1.52 
Age (1-yr increment) 0.0744 0.00636 <0.0001 0.0740 0.00643 <0.0001 -0.54 1.10 
Education (1-yr increment) -0.114 0.0164 <0.0001 -0.116 0.0165 <0.0001 1.75 0.61 
T → Clinical MCI         
Intercept (prior = normal) -4.272 0.187 <0.0001 -4.287 0.187 <0.0001 0.35 0.00 
Intercept (prior = amnestic) -3.538 0.237 <0.0001 -3.496 0.236 <0.0001 -1.19 -0.42 
Intercept (prior = mixed) -2.574 0.176 <0.0001 -2.600 0.179 <0.0001 1.01 1.70 
Age (1-yr increment) 0.133 0.0140 <0.0001 0.133 0.0141 <0.0001 0.00 0.71 
APOE-ε4 (Y vs. N) 0.607 0.190 0.0015 0.617 0.190 0.0012 1.65 0.00 
T → Dementia         
Intercept (prior = normal) -5.520 0.309 <0.0001 -5.538 0.311 <0.0001 0.33 0.65 
Intercept (prior = amnestic) -4.751 0.378 <0.0001 -4.713 0.378 <0.0001 -0.80 0.00 
Intercept (prior = mixed) -3.529 0.260 <0.0001 -3.523 0.261 <0.0001 -0.17 0.38 
Age (1-yr increment) 0.165 0.0206 <0.0001 0.165 0.0207 <0.0001 0.00 0.49 
APOE-ε4 (Y vs. N) 0.939 0.270 0.0005 0.919 0.271 0.0007 -2.13 0.37 
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Table 4.8. Continued 
Parameter 
No scaling parameters 
(Model 1*) 
Scaling parameters 
(Model 2*) Estimate
 % 
Change  
SE  
% Change Estimate SE p Estimate SE p 
T → Death         
Intercept (prior = normal) -3.257 0.165 <0.0001 -3.280 0.165 <0.0001 0.71 0.00 
Intercept (prior = amnestic) -3.599 0.262 <0.0001 -3.573 0.260 <0.0001 -0.72 -0.76 
Intercept (prior = mixed) -2.320 0.189 <0.0001 -2.354 0.192 <0.0001 1.47 1.59 
Age (1-yr increment) 0.174 0.0120 <0.0001 0.174 0.0120 <0.0001 0.00 0.00 
Sex (F vs. M) -0.399 0.153 0.0092 -0.382 0.153 0.013 -4.26 0.00 
Baseline hypertension (Y vs. N) 0.369 0.151 0.015 0.375 0.151 0.013 1.63 0.00 
T → Dropout         
Intercept (prior = normal) -4.412 0.214 <0.0001 -2.865 0.802 0.0004 -35.06 274.77 
Intercept (prior = amnestic) -4.0203 0.308 <0.0001 -2.369 0.825 0.0042 -41.07 167.86 
Intercept (prior = mixed) -3.190 0.232 <0.0001 -1.718 0.770 0.026 -46.14 231.90 
Age (1-yr increment) 0.0566 0.0166 0.0007 0.0580 0.0165 0.0005 2.47 -0.60 
Baseline hypertension  (Y vs. N) 0.637 0.234 0.0067 0.630 0.233 0.0070 -1.10 -0.43 
Education  
(1-yr increment) 
-- -- -- -0.0972 0.0489 0.047 -- -- 
Clinical MCI → Dementia         
Intercept (prior = clinical MCI) -1.566 0.273 <0.0001 -1.559 0.272 <0.0001 -0.45 -0.37 
Sex (F vs. M) 0.741 0.335 0.028 0.728 0.335 0.030 -1.75 0.00 
Clinical MCI → Death         
Intercept (prior = clinical MCI) -2.148 0.341 <0.0001 -2.210 0.349 <0.0001 2.89 2.35 
Age (1-yr increment) 0.0772 0.0338 0.023 0.0823 0.0343 0.017 6.61 1.48 
Clinical MCI → Dropout         
Intercept (prior = clinical MCI) -2.263 0.263 <0.0001 -2.263 0.262 <0.0001 0.00 -0.38 
Scaling Parameters         
Prior = amnestic MCI 1.00 0.00 -- 0.619 0.175 0.0004 -- -- 
Prior = mixed MCI 1.00 0.00 -- 1.0860 0.212 <0.0001 -- -- 
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Table 4.9. Reduced model fit comparison: age depends on prior state, all other beta coefficients are independent of the prior 
state (T: normal cognition, amnestic MCI, or mixed MCI). 
Parameter 
No scaling parameters 
(Model 3*) 
Scaling parameters 
(Model 4*) Estimate
 % 
Change  
SE  
% Change Estimate SE p Estimate SE p 
T → Amnestic MCI         
Intercept (prior=normal) -1.276 0.0819 <0.0001 -1.271 0.0833 <0.0001 -0.39 1.71 
Intercept (prior=amnestic) -1.0479 0.112 <0.0001 -0.990 0.108 <0.0001 -5.53 -3.57 
Intercept (prior=mixed) -1.546 0.136 <0.0001 -1.553 0.141 <0.0001 0.45 3.68 
Age (1-yr increment, 
prior=normal) 
0.0329 0.00767 <0.0001 0.0346 0.00789 <0.0001 5.17 2.87 
Age (1-yr increment,  
prior=amnestic MCI) 
0.0342 0.0135 0.011 0.0268 0.0132 0.043 -21.64 -2.22 
Age (1-yr increment,  
prior=mixed MCI) 
0.0913 0.0406 0.025 -- -- -- -- -- 
Sex (F vs. M) -0.204 0.0882 0.021 -0.202 0.0879 0.022 -0.98 -0.34 
T → Mixed MCI           
Intercept (prior=normal) 0.355 0.266 0.18 0.356 0.267 0.18 0.28 0.38 
Intercept (prior=amnestic) 0.387 0.280 0.17 0.444 0.279 0.11 14.73 -0.36 
Intercept (prior=mixed) 1.888 0.264 <0.0001 1.878 0.264 <0.0001 -0.53 0.00 
Age (1-yr increment, 
prior=normal) 
0.0839 0.00810 <0.0001 0.0859 0.00833 <0.0001 2.38 2.84 
Age (1-yr increment,  
prior=amnestic MCI) 
0.0739 0.0151 <0.0001 0.0655 0.0148 <0.0001 -11.37 -1.99 
Age (1-yr increment,  
prior=mixed MCI) 
0.0566 0.00921 <0.0001 0.0565 0.00972 <0.0001 -0.18 5.54 
Education (1-yr increment) -0.118 0.0165 <0.0001 -0.117 0.0165 <0.0001 -0.85 0.00 
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Table 4.9. continued 
Parameter 
No scaling parameters 
(Model 3*) 
Scaling parameters 
(Model 4*) Estimate
 % 
Change  
SE  
% Change Estimate SE p Estimate SE p 
T → Clinical MCI         
Intercept (prior=normal) -4.178 0.184 <0.0001 -4.193 0.186 <0.0001 0.36 1.09 
Intercept (prior=amnestic) -3.504 0.254 <0.0001 -3.419 0.249 <0.0001 -2.43 -1.97 
Intercept (prior=mixed) -2.726 0.205 <0.0001 -2.726 0.208 <0.0001 0.00 1.46 
Age (1-yr increment, 
prior=normal) 
0.100 0.0225 <0.0001 0.103 0.0229 <0.0001 3.00 1.78 
Age (1-yr increment,  
prior=amnestic MCI) 
0.117 0.0327 0.0004 0.107 0.0320 0.0009 -8.55 -2.14 
Age (1-yr increment,  
prior=mixed MCI) 
0.152 0.0209 <0.0001 0.151 0.0212 <0.0001 -0.66 1.44 
APOE-ε4 (Y vs. N) 0.604 0.191 0.0016 0.608 0.191 0.0015 0.66 0.00 
T → Dementia         
Intercept (prior=normal) -5.620 0.365 <0.0001 -5.629 0.369 <0.0001 0.16 1.10 
Intercept (prior=amnestic) -5.107 0.550 <0.0001 -5.0157 0.541 <0.0001 -1.79 -1.64 
Intercept (prior=mixed) -3.380 0.268 <0.0001 -3.386 0.271 <0.0001 0.18 1.12 
Age (1-yr increment, 
prior=normal) 
0.186 0.0376 <0.0001 0.190 0.0379 <0.0001 2.15 0.80 
Age (1-yr increment,  
prior=amnestic MCI) 
0.215 0.0578 0.0002 0.203 0.0569 0.0004 -5.58 -1.56 
Age (1-yr increment,  
prior=mixed MCI) 
0.134 0.0269 <0.0001 0.134 0.0272 <0.0001 0.00 1.12 
APOE-ε4 (Y vs. N) 0.926 0.271 0.007 0.925 0.271 0.0007 -0.11 0.00 
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Table 4.9. continued 
Parameter 
No scaling parameters 
(Model 3*) 
Scaling parameters 
(Model 4*) Estimate
 % 
Change  
SE  
% Change Estimate SE p Estimate SE p 
T → Death         
Intercept (prior = normal) -3.322 0.176 <0.0001 -3.324 0.178 <0.0001 0.06 1.14 
Intercept (prior = amnestic) -3.393 0.284 <0.0001 -3.310 0.279 <0.0001 -2.45 -1.76 
Intercept (prior = mixed) -2.296 0.212 <0.0001 -2.323 0.217 <0.0001 1.18 2.36 
Age (1-yr increment,  
prior = normal) 
0.186 0.0159 <0.0001 0.188 0.0161 <0.0001 1.08 1.26 
Age (1-yr increment,  
prior = amnestic MCI) 
0.125 0.0350 0.0004 0.115 0.0343 0.0008 -8.00 -2.00 
Age (1-yr increment,  
prior = mixed MCI) 
0.162 0.0196 <0.0001 0.163 0.0200 <0.0001 0.62 2.04 
Sex (F vs. M) -0.390 0.153 0.011 -0.380 0.153 0.013 -2.56 0.00 
Baseline hypertension (Y vs. N) 0.362 0.151 0.017 0.358 0.151 0.018 -1.10 0.00 
T → Dropout         
Intercept (prior = normal) -2.930 0.803 0.0003 -2.946 0.804 0.0003 0.55 0.12 
Intercept (prior = amnestic) -2.475 0.833 0.0031 -2.428 0.834 0.0037 -1.90 0.12 
Intercept (prior = mixed) -1.710 0.776 0.028 -1.754 0.778 0.024 2.57 0.26 
Age (1-yr increment,  
prior = amnestic MCI) 
0.0913 0.0406 0.025 0.0829 0.0402 0.040 -9.20 -0.99 
Age (1-yr increment,  
prior = mixed MCI) 
0.0795 0.0265 0.0028 0.0805 0.0270 0.0029 1.26 1.89 
Baseline hypertension (Y vs. N) 0.618 0.234 0.0083 0.606 0.234 0.010 -1.94 0.00 
Education (1-yr increment) -0.0990 0.0489 0.043 -0.0973 0.0490 0.047 -1.72 0.20 
Clinical MCI → Dementia         
Intercept (prior = clinical MCI) -1.556 0.271 <0.0001 -1.555 0.272 <0.0001 -0.06 0.37 
Sex (F vs. M) 0.728 0.334 0.030 0.729 0.335 0.030 0.14 0.30 
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Table 4.9. continued 
Parameter 
No scaling parameters 
(Model 3*) 
Scaling parameters 
(Model 4*) Estimate
 % 
Change  
SE  
% Change Estimate SE p Estimate SE p 
Clinical MCI → Death         
Intercept (prior = clinical MCI) -2.177 0.345 <0.0001 -2.175 0.344 <0.0001 -0.09 -0.29 
Age (1-yr increment) 0.0795 0.0340 0.020 0.0794 0.0340 0.020 -0.13 0.00 
Clinical MCI → Dropout         
Intercept (prior = clinical MCI) -2.277 0.264 <0.0001 -2.261 0.262 <0.0001 -0.70 -0.76 
Scaling Parameters         
Prior = amnestic MCI 1.00 0.00 -- 0.552 0.173 <0.0001 -- -- 
Prior = mixed MCI 1.00 0.00 -- 0.917 0.212 <0.0001 -- -- 
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Figure 4.1. Diagram of one-step transitions possible between adjacent subject visits in the 
Biologically Resilient Adults in Neurological Studies (BRAiNS) cohort study. Double-headed 
arrows indicate back transitions are possible from more impaired to less impaired states. 
Dementia, dropout, and death are absorbing states. 
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CHAPTER FIVE 
Conclusion 
 
Summary 
Dementia is increasingly recognized as a major and growing threat to public 
health worldwide,111 and there is a critical need for prevention and treatment strategies. 
However, it is necessary that appropriate methodologies are used in the identification of 
risk factors. The purpose of this dissertation research was to develop further the body of 
literature featuring Markov chains as an analytic tool for data derived from longitudinal 
studies of aging and dementia. Data drawn from the University of Kentucky’s 
Alzheimer’s Disease Center’s (UK ADC) Biologically Resilient Adults in Neurological 
Studies (BRAiNS) cohort, which was established in 1989 and follows adults age 60 years 
and older who are cognitively normal at baseline to death, were used to  conduct three 
studies: (1) “Mild cognitive impairment: Statistical models of transition using 
longitudinal clinical data,” (2) “Self-reported head injury and risk of cognitive 
impairment and Alzheimer’s-type pathology in a longitudinal study of aging and 
dementia, ” and (3) “Incorporating prior-state dependence among random effects and beta 
coefficients improves multistate Markov chain model fit.” The major findings from these 
studies are summarized below. 
Chapter Two examined risk factors associated with both cognitive test-based and 
clinically determined forms of mild cognitive impairment (MCI). MCI has existed as a 
clinical diagnosis only since 2004.10 These initial criteria were independent of suspected 
etiology, which meant that forms of cognitive impairment due treatable (e.g., depression) 
and untreatable (e.g., Alzheimer’s disease) causes of MCI were considered the same 
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diagnostic entity.  This conflation of etiologies, along with the tendency of large 
observational studies to determine MCI based on only a single measure of cognition, such 
as the Mini-Mental State Examination, led to the perception that MCI is unstable and that 
recovery to normal cognition frequently occurs. It was demonstrated in Chapter Two, 
however, when a suspected neurodegenerative etiology is included in the MCI criteria, 
and adequate follow-up is available to characterize the trajectory of participants, MCI is 
in fact quite stable. Apparent recoveries to normal cognition are due to misclassification 
or underlying medical conditions.  
Other important findings from this chapter concern the role of test-based 
cognitive impairments in predicting future clinical states. Although test-based amnestic 
impairments (i.e., episodic memory) in this study were highly transient in nature, with 
almost 60% returning to normal cognition at the next assessment, they were still 
predictive of clinically determined impairment (  for clinical MCI = 2.3 [95% CI: 1.3-
4.0]). More striking, however, was the association between non-amnestic impairments  
(i.e., language, attention, or executive function) and clinical impairment (  for clinical 
MCI = 4.8 [95% CI: 2.9-7.8] and  for dementia = 4.9 [95% CI: 2.6-9.3]. The bottom 
line is that there are clinically significant cognitive impairments that can be detected at 
least one year before the criteria for a clinical diagnosis are met. While those impairments 
will often not be followed by a clinical impairment within one year, and thus should 
not—especially in the absence of longitudinal evidence of impairment—be used as the 
basis for a diagnosis by clinicians, they do place individuals at an increased risk of 
eventual MCI and dementia. 
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Chapter Three represents the first application of a Markov chain to analysis of 
self-reported head injury as a risk factor for cognitive impairment, dementia, and death, 
as well as the first study to incorporate both longitudinal observational and 
neuropathological data. This study confirmed that head injury is a risk factor for both 
dementia and death, and this was the first study to show that head injury is also a risk 
factor for MCI. Additionally, the inclusion of neuropathological data in the analysis shed 
some light on earlier findings from case-control studies that suggested that only men are 
at increased risk of dementia following a head injury. Among the subset of participants 
who came to autopsy, men with a history of head injury had significantly increased 
numbers of mean diffuse and neuritic plaques in both the neocortical and medial temporal 
areas. There was no observable difference between women with a history of head injury 
and women without.   
While Fleminger and colleages (2003) suggested that women may be offered 
protection against head injury by the presence of female sex hormones,69 the BRAiNS 
data suggest that men and women of this generation may have qualitatively different head 
injury exposures. Men in this study tended to have injuries that resulted in longer periods 
of unconsciousness. Moreover, men in this study also tended to participate in activities—
like boxing, football, and military service—that could lead to repeated blows to the head 
that do not result in loss of consciousness. Despite growing evidence that it is cumulative 
lifetime exposure that determines chronic effects,101 studies of head injury are typically 
focused on only the most severe injuries, i.e., those resulting a loss of consciousness or, 
in many cases, the subset of those injuries requiring medical attention. Thus, perhaps it is 
not sex hormones that protected the women included in earlier studies but rather the 
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tendency of men to sustain more severe and/or frequent injuries. Severity of injury was 
not considered in Fleminger et al.’s analysis.  
Chapter Four shifted focus from risk factors for MCI and dementia to Markov 
model mechanics. Markov chains are rather complex, and there are many possibilities as 
to how they may be constructed. Song et al. (2011) proposed scaling the subject-specific 
random effects based on the observed prior state and demonstrated that the addition of 
these scaling parameters improved model fit as measured by Akaike’s information 
criterion.31  These prior-state dependent scaling parameters, along with prior-state 
dependent beta coefficients, were evaluated in an application to the data from the 
BRAiNS cohort. Major findings from this study include the confirmation that scaling the 
random effects based on the prior state does improve model fit, as measured by 
likelihood ratio tests, along with the finding that treating the effect of age as prior-state 
dependent not only improves model fit but also reveals previously hidden associations. 
When the effect of age is independent of the prior state, it has no significant effect on a 
participant’s probability of dropping out of the study. However, when the effect of age 
depends on the prior state, participants with a non-amnestic impairment at the previous 
assessment are more likely to drop out with older age: a one-year increase in age raises 
the odds of dropping out by 8% (95% CI: 3%-14%).  
Strengths and Limitations 
 Markov chains are an underutilized tool in the analysis of data from longitudinal 
studies of aged volunteers since death is always a competing risk93 for any outcome of 
interest. Although they have the advantages of flexibility (i.e., the number of transient 
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and absorbing states can vary), handling correlated observations, as well as handling 
multiple outcomes and competing risks, they can be quite complicated to implement as 
no “off-the-shelf” software is available. A fair amount of technical knowledge is 
necessary to program the analysis within procedures like PROC NLMIXED, and there is 
little guidance available in the literature on how best to fit these models, which can have 
easily over 100 parameters in a full model evaluating multiple risk factors. Other 
limitations of the Markov model include sensitivity to sparse cells, which can limit the 
evaluation of interaction terms, and the need for mature datasets where most participants 
have reached an absorbing state. 
 A major strength of this dissertation is that the data were drawn from a large, 
clinically well characterized cohort with lengthy (mean 10.3±4.7 assessments) follow-up. 
Adequate follow-up helps reduce misclassification errors, as demonstrated in Chapter 
Two, as well as mitigates the sparse cell problems that can limit the utility of Markov 
chain analyses. At the same time, however, it is crucial to note that the participants in the 
BRAiNS cohort are not representative of the general population of individuals age 60 
years and older. Study volunteers are highly educated compared to their peers nationally, 
and thus the generalizability of the results may be limited. However, the concept of 
cognitive reserve would imply that these participants are less susceptible to risk factors 
that would affect their peers. Thus, risk factors identified in the studies of this dissertation 
should also affect the general population of aged individuals, whose brains may be less 
able to compensate for neuropathological insults. 
 Furthermore, despite the large sample there still were not enough participants with 
dementia to separate the dementia state into etiologically determined categories. 
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Although most cases of dementia in any older population will involve Alzheimer’s 
disease, up to 40% may be due to some other cause entirely.7 In addition, multiple 
pathologies may be present, especially as participants reach their mid-80s. Thus, 
information about risk factors for specific dementing diseases is inevitably lost when all 
dementias are treated as being the same.   
 Other limitations include the possibility of uncontrolled confounding and effect 
modification. Again, because of the sparse cell problem, the ability to test interactions 
terms was somewhat limited.  Furthermore, despite the prospective cohort design, data on 
time-varying comorbidities and measurements—such as blood pressure—are limited, and 
key social and lifestyle factors, such as characterization of time devoted to hobbies (e.g., 
reading, travelling, music) as well as diet and exercise routines are not available.  
 Finally, the addition of the dropout state to the Markov chain is a strength of this 
dissertation. Prior applications of the Markov chain to the BRAiNS cohort excluded 
participants who dropped out of the study, as was done in Chapter Two. The inclusion of 
the dropout state in Chapters Three and Four makes more efficient use of the cohort data 
and provides a method of identifying risk factors that may aid in refining participant 
retention efforts.  
Future Research 
There are several avenues for future research suggested by the studies in this 
dissertation. First, additional research into Markov chain model fitting is needed. As 
mentioned above, there is nothing in the literature to provide guidance about how best to 
fit these models. Since fitting the models is expensive in terms of time and computational 
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resources, particularly when random effects are included, methods are needed that clearly 
demonstrate the advantages and disadvantages of various selection algorithms.  
In Chapter Two, it is posited that a clinical diagnosis of MCI is a semi-absorbing 
state from which participants do not recover. While that may be the case at the UK ADC, 
it is not necessarily true for all patients in all study populations. Additional data are 
needed to evaluate the true stability of the clinical MCI diagnosis, and more importantly, 
to evaluate its utility as a clinical entity distinct from dementia.  
The study of head injury as a risk factor for AD remains underdeveloped, and 
neuropathological data obtained from participants in other longitudinal observational 
studies need to be evaluated. In addition, prospective studies, such as those being 
conducted at all 29 federally funded Alzheimer’s Disease Centers, should be collecting 
more detailed data about such injuries. Currently, ADCs are only required to determine 
whether a head injury with a loss of consciousness (LOC) has occurred, and if so whether 
it lasted more or less than five minutes, and whether there are chronic effects.24 These 
data should be expanded to capture, at minimum, the age at injury, the estimated length 
of LOC, and whether medical treatment was obtained immediately following the injury.  
As mentioned in Chapter Four, additional research into the transient states in the 
Markov chain is necessary. There is a strong association between the test-based 
impairments that determine the transient states in the Markov chain and risk of future 
clinical impairment, despite the heavy back flow of participants from these states to 
normal cognition. The criteria that determine these states are somewhat arbitrary, 
however, and additional research is needed to determine the influence of cutpoints for 
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impairment (currently set at 1.5. standard deviations below the expected mean score for 
age) and the number of poor scores necessary to be classified as impaired (currently only 
one is needed) on the back transition rate.   
Finally, as noted above, there is a critical need for studies with enough 
participants and follow-up to examine risk factors and cognitive profiles for mixed 
dementias, i.e., dementias resulting from multiple brain diseases. For example, of the 
autopsied participants in the current study, 20/81 (24.7%) of individuals with a 
pathological diagnosis of AD also had either Lewy body disease, hippocampal sclerosis, 
or cerebrovascular disease sufficient to cause dementia. There are clear implications here 
for clinical trials, which are likely to enroll participants with mixed pathologies while 
working under the assumption that only AD is present.  
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Appendix A. Model selection strategy 
To fit the model to the data, a modified backward selection algorithm was used due to the 
large number of parameters in the full models (e.g., p = 129 in Chapter 3). First, the full 
model was fit. Next all parameters with a p-value greater than or equal to 0.25 were 
removed and the model was refit; baseline smoking, which was specified in the model as 
three indicator variables, was only removed when all three levels of smoking had p-
values at or above the cutoff.  
The reduced model was compared to the full model with a likelihood ratio (LR) test. If 
the LR test had a p-value > 0.05, the reduced model was accepted. This process was 
repeated until all parameters remaining in the model were significant at the α = 0.10 
level. At this point, predictor variables were removed one at a time based on the highest 
p-value until all remaining predictors were significant at the α = 0.05 level. 
Table A.1. Chapter 3 model fitting iteration history. 
Model Parameters  -2 Log-L 
α to stay 
in next 
model 
LR (current vs. 
previous model) 
p 
Full 129 13326 0.25 -- -- 
Reduced 1 92 13341 0.20 15 0.99 
Reduced 2 78 13350 0.15 9 0.83 
Reduced 3 74 13357 0.10 7 0.14 
Reduced 4 67 13368 -- 11 0.14 
Final 47 13409 -- 41 0.037 
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